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Chapter 1                                                                                                 Introduction
INTRODUCTION
                             In pharmacology  Bioavailability (BA) is a subcategory of
absorption and is the fraction of an administered dose of unchanged drug that reaches
the systemic circulation which is one of the principal pharmacokinetic properties of
drugs.  By  definition  when  a  medication  is  administered  intravenously  its
bioavailability is 100% [1] however when a medication is administered via other routes
(such as oral) its bioavailability generally decreases (due to incomplete absorption and
first-pass metabolism) or may vary from patient to patient. Bioavailability is one of
the essential tools in pharmacokinetics  as bioavailability must be considered when
calculating dosages for non-intravenous routes of administration.
                             Bioequivalence study (BE) is a comparative study of bioavailability
among  drug  products  that  contain  the  same  active  agents.  Bioavailability  and
bioequivalence of  drug products and drug product selection have emerged as critical
issues  in  pharmacy  and  medicine  during  the  last  three  decades.  Concern  about
lowering health costs is resulted in tremendous written increase in the use of generic
drug products currently about one half of all prescriptions written are for drugs that
can be substituted with a generic drug.
                              This circumstantial growth of generic pharmaceutical industry [1]
and the abundance  of  multisource  products  have prompted some questions among
healthy professionals  and scientists  regarding  the therapeutic  equivalency of  these
products. Inherent in the currently accepted guidelines for product substitution is the
assumption that  a  generic  drug considered to be equivalent  to a brand name drug
would elicit the same clinical effect.
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                                Numerous papers in the literature indicate that there is concern
that  the  current  standards  for  approval  of  generic  drugs  may  not  always  ensure
therapeutic equivalence. The availability of different formulations of the same drug
substance given at the same strength and in the same dosage form poses a special
challenge to health care professionals.
                                 This study is comparative bioequivalence study of Trimebutine
200 mg capsules and  Digedrat®  200 mg capsules of Reference brand in  48 healthy,
adult, human, male and non-pregnant female subjects under fasting conditions.
Trimebutine maleate is used to regulating effects of on lower gastrointestinal tract and
to treat the irritable bowel syndrome.
BIOAVAILABILITY (BA):  
                                  Bioavailability is defined as: “The rate and extent to which the
active  ingredient  or  active  moiety  is  absorbed  from a  drug  product  and  becomes
available at the site of action.”[2]     
Bioavailability[3]:
• It  is  the  fraction  of  unchanged  drug  reaching  the  systemic  circulation
following administration by any route. 
• To exert an optimal therapeutic action, an active moiety should be delivered to
its site of action in an effective concentration for the desired period
• This defines how much drug needs to be administered to achieve therapeutic
effect.
• The influence of route of administration on drug’s bioavailability is: 
                       Parenteral > oral > rectal > topical
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• Intravenous  injection  of  a  drug  results  in  100%  bioavailability  as  the
absorption process is bypassed. In such cases the dose available to the patient
called as the bioavailable dose is often less than the administered dose. 
• Estimation of bioavailability is a means of predicting the clinical efficacy of a
drug.
•  Bioavailability testing measuring the rate and extent of drug absorption is a
way to obtain evidence of the therapeutic utility of a drug product.
  Fraction of administered dose that enters the systemic circulation                     
                                  F   =   Bioavailable dose 
                                            Administered dose 
It ranges from 0 to 1 Bioavailability normally expressed as %. 
TYPES OF BIOAVAILABILITY [4][5]:  
Absolute bioavailability (F):
• When  systemic  availability  of  drug  administered  orally  is  determined  in
comparison to its intravenous administration is called absolute bioavailability.
• Its  determination  is  used  to  characterize  a  drug’s  inherent  absorption
properties from the extra vascular site.
• Absolute bioavailability  =  [AUC]ev /(Dose)ev   
                                                                   [AUC]iv /(Dose)iv           
(ev-extravascular & iv- intravenous)
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Relative Bioavailability (Fr)
• When systemic availability of drug after oral administration is compared with
that of an oral  standard of same drug (such as an aqueous or non aqueous
solution or suspension) it is referred as relative bioavailability.
• It is used to characterize absorption of drug from its formulation 
Relative Bioavailability ==   [AUC]test /(Dose)test 
 [AUC]std/(Dose)std 
• Before the therapeutic effect of an orally administered drug can be realized the
drug must be absorbed 
Supra bioavailability [6]:
Supra  bioavailabilty  is  a  term  used  when  a  test  product  displays  larger
bioavailability than the reference product.  Such formulations are usually not to be
accepted as therapeutically equivalent to the existing reference product.
General Objectives Of Bioavailability Studies
Bioavailability  studies  are  important  in  the determination  of  influence  of
excipients patient related factors and possible interaction with other drugs on
the efficiency of absorption.
i. Development  of  new  formulations  of  the  existing  drugs  e.g.  innovator  vs
generic.  Bioequivalence  study  looking  for  similarity  of  F  and  ka  values
between products. 
ii. one type of dosage form with another e.g.  tablet versus intravenous dosage
form  or  regular  tablet  with  sustained  release  tablet.  Bioavailability  study
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where ka and F are to be determined. Changes in ka may be intentional (slow
release) whereas F values should be similar.[7]
Factors Influencing Bioavailability
The absolute bioavailability of a drug when administered by an extra vascular
route is  usually  less  than one (i.e.  F<1).  Various  physiological  factors  reduce  the
availability of drugs prior to their entry into the systemic circulation. [8]
Such factors may include but are not limited to:
• Physical properties of the drug (hydrophobicity, pKa, solubility)
• The drug formulation (immediate release, excipients used, manufacturing
methods,  modified release - delayed release, extended release, sustained
release, etc.)
• If the drug is administered in a fed or fasted state
• Gastric emptying rate
• Circadian differences
• Enzyme induction/inhibition by other drugs/foods.
•  Disease state eg: Hepatic insufficiency, poor renal function
 Each  of  these  factors  may  vary  from  patient  to  patient  (inter-individual
variation)  and  indeed  in  the  same  patient  over  time  (intra-individual  variation).
Whether a drug is taken with or without food will affect absorption other drugs taken
concurrently may alter absorption and first-pass metabolism, intestinal motility alters
the dissolution of the drug and may affect the degree of chemical degradation of the
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drug  by  intestinal  micro  flora.  Disease  states  affecting  liver  metabolism  or
gastrointestinal function will also have an effect.
              Absolute bioavailability compares the bioavailability (estimated as area
under the curve, or AUC) of the active drug in systemic circulation following non-
intravenous  administration  (i.e.,  after  oral,  rectal,  transdermal,  subcutaneous
administration)  with  the  bioavailability  of  the  same  drug  following  intravenous
administration. [9]
              Relative bioavailability is extremely sensitive to drug formulation. Relative
bioavailability is one of the measures used to assess bioequivalence between two drug
products as it  is the Test/Reference ratio of AUC. The maximum concentration of
drug in plasma or serum (Cmax) is also usually used to assess bioequivalence.
     If the size of the dose to be administered is same then bioavailability of a
drug from its dosage form depends upon three major factors:[10]
• Pharmaceutical  factors related to physiochemical properties of the drug and
characteristics of dosage form.
• Patient related factors.
• Route of administration.
METHODS FOR ASSESSING BIOAVAILABILITY [10]:
        The methods useful in quantitative evaluation can be divided into 2 categories
I.Pharmacokinetic methods (indirect method)           
                  These are very widely used and based on the assumption that the
pharmacokinetic profile reflects the therapeutic effectiveness of a drug. Thus these are
indirect methods. 
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There are 2 methods in this type
             A) Plasma level-time studies
             B) Urinary excretion studies.
II. Pharmacodynamic methods (direct method)
                            These methods are complementary to pharmacokinetic approaches
and involve direct measurement of drug effect on patho physiological process as a
function of time.
 The two pharmacodynamic methods   are:
             A) Acute pharmacological response
             B) Therapeutic response.  
PHARMACOKINETIC PARAMETERS[10]
Cmax −  Maximum measured plasma concentration after the administration of
single dose of the drug expressed in terms of µg/ml or ng/ml.
AUC0-t
 
– The area under the plasma concentration versus time curve from time
zero to the last  time point  with measurable  concentration calculated by the linear
trapezoidal method.
AUC₀-∞−  The area under the plasma concentration versus time curve from
time zero to time infinity. AUC0-∞ is calculated as the sum of the AUC0-t   plus the ratio
of the last measurable concentration to the elimination rate constant. 
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Tmax:     Time of maximum measured plasma concentration. If the maximum
value occurs at more than one point Tmax is defined as the first point with this value in
each period. Gives indication of the rate of absorption expressed in terms of hours or
minutes.
 Kel: Apparent first order elimination or terminal rate constant calculated from
a semi-log plot of the plasma concentration versus time curve.  
T1/2:  Apparent first-order terminal elimination half life will be calculated as
0.0693/Kel.
            The  various  pharmacodynamic  parameters  which influence  the  above
mentioned pharmacokinetic parameters are:
Minimum Effective Concentration (MEC):
It  is  defined as  the minimum concentration  of  drug in  plasma required  to
produce the therapeutic effect. It reflects the minimum concentration of the drug at the
receptor site to elicit the desired pharmacologic response. The concentration of drug
below MEC is said to be in the sub therapeutic level.
Maximum Safe Concentration (MSC)
Also called as minimum toxic concentration (MTC) it is the concentration of
the  drug  in  plasma  above  which  adverse  or  unwanted  effects  are  precipitated.
Concentration of drug above MSC is said to be in the toxic level.
Onset of Action
The beginning of pharmacologic response is called as onset of action. It occurs
when the plasma drug concentration exceeds the required MEC.
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Onset Time
It  is  the time required  for  the drug to  start  producing pharmacologic  response.  It
corresponds to the time of plasma concentration to reach MEC after administration of
drug.
Duration of Action
The time period for which the plasma concentration of drug remains above the
MEC level is called as duration of drug action.
Therapeutic Range
The drug concentration between MEC and MSC represents the Therapeutic range
FIGURE 1: Pharmacokinetic parameters.
Bioavailability is needed for
 Drugs having low therapeutic index e.g. cardiac glycosides, quinidine, phenytoin
etc.
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 Drugs whose peak  levels are required for the  effect  of drugs e.g.  phenytoin,
phenobarbitone,  primidone,  sodium  valporate,  anti-hypertensives,  antidiabetics
and antibiotics.
 Drugs that are absorbed by an active transport e.g. amino acid analogues, purine
analogues etc.
 Drugs  which  are  disintegrated  in  the  alimentary  canal  and  liver
e.g.chlorpromazine etc., or those which under go first pass metabolism.
 Formulations  that  give  sustained  release  of  drug  formulations  with  smaller
disintegration time than dissolution rate and drugs used as replacement therapy
also warrant  bioavailability testing.  In  addition any new formulation has to be
tested for its bioavailability profile.
BIOEQUIVALENCE (BE) [8] :
 Chemical equivalents which when administered to the same individuals in the
same dosage regimen will result in comparable bioavailability. Bioequivalence gained
increasing attention during the last  40 years  after  it  became evident that marketed
products having the same amounts of the drug may exhibit marked differences in their
therapeutic  responses.  When  drug  products  are  administered  to  individuals  the
investigator inevitably finds differences  in one or more of the variables measured.
These  differences  are  due  partly  to  factors  related  to  dosage  form  and  partly  to
biological  factors  unique  to  each  individual  since  each  person  has  his  own
characteristics  for  absorption,  metabolism  and  excretion  of  each  drug.  Through
appropriate use of statistical procedures it is possible to identify the variations that
result from differences among individuals and thus to isolate those that result from
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differences  in the bioavailability of the drug products.  Generally these differences
were  well  correlated  to  dissimilar  drug  plasma levels  caused  mainly by  impaired
absorption.  Now a considerable  body of  evidence  has  accumulated indicating that
drug response is better correlated with the plasma concentration or with the amount of
drug in the body than with the dose administered. Consequently on the basis of simple
pharmacokinetic concepts and parameters bioavailability and bioequivalence studies
have been established as acceptable surrogates for expensive complicated and lengthy
clinical trials and are used extensively worldwide to establish and ensure consistent
quality and a reliable therapeutically effective performance of marketed dosage forms
          Bioequivalence studies compare both the rate and extent of absorption of
various multisource drug formulations with the innovator (reference) product on the
basis that if two formulations exhibit similar drug concentration-time profiles in the
blood/plasma they should exhibit similar therapeutic effects. 
Three situations have thus been defined in which bioequivalence studies are required
• When the  proposed  marketed  dosage  form is  different  from that  used   in
pivotal clinical trials. (Edwards., 1990) When significant changes are made in
the manufacture of the marketed formulation.  
• When  a  new  generic  formulation  is  tested  against  the
innovator’s  marketed  product.  Comparative  evidence  may require  not  only
studies in a fasting condition but following a specified meal. The latter permit
drug formulations to be evaluated under "stressed conditions". If it is shown
that  competitive  products  are  bioequivalent  under  both  fasting  and  fed
conditions there is greater confidence that they are therapeutically equivalent
when used in patients. Bio-equivalent simply means that one brand or dosage
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form of a drug or supplement is equivalent to a reference brand or dosage form
of the same drug or supplement in terms of various bioavailability parameters
measured via in-vivo testing in human subject.
.
FACTORS INFLUENCING BIOEQUIVALENCE [12]:
 Delayed gastric emptying,
 Stimulation of bile flow,
 Change in gastrointestinal (GI) pH,
 Increase splanchnic blood flow,
 Change in luminal metabolism of a drug substance,
 Physical or chemical interaction with a dosage form or a drug substance.
 Food  can  change  the  BA  of  a  drug  and  hence  can  influence  the  BE
between test and reference products.
TYPES OF BIOEQUIVALENCE [4],[13]:
 Chemical equivalence:
It  indicates  that  two or  more  drug  products  that  contain  the  same labeled
chemical substance as an active ingredient in the same amount.
 Pharmaceutical equivalence:
It is a relative term which denotes that the drug  substance  in  two  or  more
forms are identical in strength, quality, purity, content uniformity, disintegration and
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dissolution  characteristics.  They  may  however  differ  in  containing  different
excipients.
 Therapeutic equivalence:        
It  indicates  that  two  or  more  drug  products  that  contain  the  same
therapeutically  active  ingredient  elicit  identical  pharmacological  effects  and  can
control the disease to the same extent. 
TYPES OF BIOEQUIVALENCE STUDIES:
 In vivo studies
 In vitro studies
In Vivo Studies:
The following points are used in assessing the need for in vivo studies:
 Oral immediate release products with systemic action.
 Indicated for serious conditions requiring assured response.
 Narrow therapeutic margin.
 Pharmacokinetics  complicated  by  absorption  lesser  than  70%  or  non
linear kinetics, presystemic elimination greater than 70%.
 Unfavourable  physiochemical  properties  like  low solubility,  metastable
conditions, instability,etc.
 Non- oral immediate release products.
 Modified release products with systemic action.
Dept.of Pharmacology                                                            JKKMMRF College of Pharmacy13
Chapter 1                                                                                                 Introduction
In Vitro Studies [14]:
If  none of  the  above criteria  is  applicable  comparative  in  vitro  dissolution
studies will   suffice. In vitro studies are conducted in cases where
 The product is intended for topical administration (Cream, ointment gel) for
local effect.
 The  product  is  for  oral  administration  but  not  intended  to  be  absorbed
(antacid or opaque medium).
 The product is administered by inhalation as a gas or vapor.
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GENERAL CONCEPTS OF DESIGN AND CONDUCT OF STUDIES
              
         The design and conduct of the study should follow EC-rules for Good
Clinical Practice including reference to an Ethics Committee [15]
             As recommended by the US FDA (1992) in most bioequivalence trials
a test formulation is compared with the standard / innovator reference formulation in a
group of normal healthy subjects (18-45 yr) each of whom receive both the treatments
alternately in a crossover fashion (two-period, two-treatment crossover design) with
the  two  phases  of  treatment  separated  by  a  washout  period  of  generally  a  week
duration  but  may  be  longer  (a  minimum  time  equivalent  to  5  half-lives)  if  the
elimination half-life of the drug is very long. The treatment is assigned to each subject
randomly but an equal number of subjects receive each treatment in each phase. Thus
in case of two treatments A and B one group gets the treatment in the order AB and
the second group in the reverse order BA. This is done to avoid the occurrence of
possible sequence or period effects. A similar allocation is done in case of a three-
treatment crossover design (three-period, three-treatment crossover design).
           For  several  drugs a great  inter-subject variability in clearance is
observed. The intra-subject  coefficient  of variation (approximately 15%) is usually
substantially smaller than that between subjects (approximately 30%) and therefore
crossover designs are generally recommended for bioequivalence studies [16]
          The  primary advantage  of  the crossover  design  is  that  since  the
treatments  are  compared  on  the  same subject  the  intersubject  variability does  not
contribute  to  the  error  variability.  If  the  drug  under  investigation  and/or  its
metabolites has an extremely long half-life a parallel group design may be indicated.
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In  a  parallel  group  design  subjects  are  divided  randomly  into  groups  each  group
receiving one treatment  only.  Thus each subject  receives  only one treatment.  In  a
parallel design although one does not have to worry about sequence period or carry
over effects or dropouts during the study the inter-subject variability being very high
the sensitivity of the test is considerably reduced thus requiring a larger number of
subjects compared to a crossover design to attain the same sensitivity.
            Inherent in both the crossover and parallel designs are the three
fundamental statistical concepts of study design namely 
 Randomization 
 Replication and Error control. 
• Randomization
It  implies  allocation  of  treatments  to  the  subjects  without  selection  bias.
Consequently  randomization is  essential  to  determine  an  unbiased  estimate  of  the
treatment effects.
• Replication
It implies  that  a  treatment  is  applied  to  more  than  one  experimental  unit
(subject) to obtain more reliable estimates than is possible from a single observation
and hence provides a more precise measurement of treatment effects. The number of
replicates (sample size) required will  depend upon the degree of differences  to be
detected and inherent variability of the data. Replication is used concomitantly with
Error control to reduce the experimental error or error variability. 
More commonly used replicated crossover designs to compare two formulations
are: 
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 Four-sequence and two-period design (Balaam’s design)  
 Two-sequence and four-period design
 Four-sequence and four-period design        
 Two-sequence and three-period design          
 Crossover design for three medications (Williams’ design) 
 Crossover design for four medications (Williams’ design)
Crossover design for two medications (t – test; r -- reference)
2x2 crossover design:
This  is  a  conventional  not-replicated  design  with  two  formulations,  two
periods, two sequences that may be represented as follows:
                                        
Each individual is randomly assigned to RT or TR sequence in two dosage
periods. That is, individuals assigned to RT (TR) sequence receive formulation R (T)
in the first dosage period and formulation T (R) in the second dosage period.
Randomization for a 2x2 crossover study may be carried out through tables of
random numbers or randomization procedures implemented by statistical software.
Replicated crossover design
This design is recommended for bioequivalence studies of formulations with
modified-release  dosage  or  highly  variable  products  (intra-individual  variation
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coefficient ≥30%), including the quick-release, and modified-release ones and other
oral administration products.
The same test and reference formulation batches shall be used for this design
for replicated administration. The periods shall be sufficiently spaced (washout) to
assure non-existence of carryover effects.
More  commonly  used  replicated  crossover  designs  to  compare  two
formulations are
Four-sequence and two-period design (Balaam’s design)
In this design test (T) and reference (R) will be taken in two period and four
sequence pattern in order to compare two formulations of a drug.  
             
Two-sequence and four-period design
In  this  design there  will  be four  periods  and two sequences.  To know the
typical drug concentration variations in human subjects regarding test and references,
number of periods can be increased. 
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Four-sequence and four-period design
Here the design consists of four periods and four sequences.  It  was a most
typical replicated crossover design.
                       
Two-sequence and three-period design
In this design subjects will undergo three period and two sequence design.      
                      
Crossover design for three medications (Williams’ design)
(Williams’ design with T1 = test 1, T2 = test 2, R = reference)
In order to compare three formulations of a drug, there are a total of three
possible comparison pairs among formulations: formulation 1 versus formulation 2,
formulation versus formulation 3, and formulation 2 versus formulation 3. 
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TYPES OF BA/BE STUDIES :
FASTING STUDY
After a overnight fast of at least 10 hrs subjects are made to continue to fast for upto 4
hrs after dosing.
FED STUDY
After  a overnight fast  of at  least 10 hrs subjects are given a high calorie-high fat
breakfast 60 min prior to administration of the drug product.
QUALITY CONTROL AND QUALITY ASSURANCE
QUALITY CONTROL:
The  principal  investigator  by  careful  planning,  assigning  responsibilities  to  well
qualified study personnel, through continuous review, verifies and maintains desired
level of quality in the study.
QUALITY ASSURANCE
Review will be carried out by the QA department to confirm that deviations if any
from approved protocol or sop are adequately documented.
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EHICAL CONSIDERATIONS
BASIC PRINCIPLES
The study will be carried out in accordance with the provisions of current versions of
ICH guidance for Good clinical practices ICMR guidance for biomedical research on
human subjects.
INSTITUTIONAL REVIEW BOARD
The protocol and informed consent will be submitted to the IRB/IEC for review. Upon
approval.
The study will be conducted as per approved protocol.
INFORMED CONSENT FORM
A process by which a subject voluntarily confirms his or her willingness to participate
in a particular  trial,  after  having been informed of all aspects of the trial  that  are
relevant to the subject's decision to participate. Informed consent is documented by
means of a written, signed and dated informed consent form. A reference copy of the
form shall be given to the respective subjects.
TERMINATION OF STUDY
The  sponsor  reserves  the  right  to  discontinue  the  study  at  any  time,  upon  IRB
approval. Reasons for the termination will be provided to the subjects and IRB. The
investigator reserves the right to discontinue the study at anytime for the reasons of
subject safety and welfare.  The institutional review board (IRB) may terminate the
study, if there are major violations of ethics or due to any serious adverse effects.
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SUBJECT COMPENSATION
The subjects will be paid an adequate compensation by the IRB on account of their
time participation in the trail and for any inconvenience caused. In case of drop outs
of subject before completion of study the compensation will be paid according to the
compensation policy.
INSURANCE POLICY
The study will be covered by an insurance contract where in all subjects participation
in any study is covered for indemnity and medical expenses.
DRAWING AND DISPOSAL OF PLASMA SAMPLES
The plasma samples should be drawn only when a proper  validated bio analytical
method is available and disposed after submission of study report.
STUDY TERMS & DEFINITIONS 
ADVERSE DRUG REACTION (ADR)
In  the  pre-approval  clinical  experience  with  a  new medicinal  product  or  its  new
usages, particularly as the therapeutic dose (s) may not be established: all noxious and
unintended responses to a medicinal product related to any dose should be considered
adverse drug reactions.  The phrase responses to a medicinal  product means that a
causal  relationship between a medicinal  product and an adverse event is at least a
reasonable possibility, i.e. the relationship cannot be ruled out.
Regarding marketed medicinal products: a response to a drug which is noxious and
unintended  and  which  occurs  at  doses  normally  used  in  man  for  prophylaxis,
diagnosis, or therapy of diseases or for modification of physiological function (see the
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ICH Guideline for Clinical Safety Data Management: Definitions and Standards for
Expedited Reporting).
ANOVA (ANALYSIS OF VARIANCE)
It is a statistical technique to identify sources of variance and estimate the degree of
variability. In most bioavailability studies, there are three readily identified sources of
variance namely formulation, subject and period. Hence it is a 3-way cross over.
ADVERSE EVENT (AE)
Any  untoward  medical  occurrence  in  a  patient  or  clinical  investigation  subject
administered a pharmaceutical product and which does not necessarily have a causal
relationship  with  this  treatment.  An  adverse  event  (AE)  can  therefore  be  any
unfavorable  and  unintended  sign  (including  an  abnormal  laboratory  finding),
symptom,  or  disease  temporally  associated  with  the  use  of  a  medicinal
(investigational)  product,  whether  or  not  related  to  the  medicinal  (investigational)
product (see the ICH Guideline for Clinical Safety Data Management: Definitions and
Standards for Expedited Reporting).
APPROVAL (IN RELATION TO INSTITUTIONAL REVIEW BOARDS)
The affirmative decision of the IRB that the clinical trial has been reviewed and may
be conducted at the institution site within the constraints set forth by the IRB,  the
institution, Good Clinical Practice (GCP), and the applicable regulatory requirements.
AUDIT
A systematic and independent examination of trial related activities and documents to
determine whether the evaluated trial related activities were conducted, and the data
were recorded, analyzed and accurately reported according to the protocol, sponsor's
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standard  operating  procedures  (SOPs),  Good  Clinical  Practice  (GCP),  and  the
applicable regulatory requirement(s).
AUDIT CERTIFICATE
A  declaration of confirmation by the auditor that an audit has taken place.
AUDIT REPORT
A written evaluation by the sponsor's auditor of the results of the audit.
AUDIT TRAIL
Documentation that allows reconstruction of the course of events.
BLINDING/MASKING
A  procedure  in  which  one  or  more  parties  to  the  trial  are  kept  unaware  of  the
treatment  assignment(s).  Single-blinding  usually  refers  to  the  subject(s)  being
unaware and double-blinding usually refers to the subject(s), investigator(s), monitor,
and in some cases data analyst(s) being unaware of the treatment assignment(s).
CASE REPORT FORM (CRF)
A  printed  optical  or  electronic  document  designed  to  record  all  of  the  protocol
required information to be reported to the sponsor on each trial subject
COMPARATOR (PRODUCT)
An investigational  or marketed product (i.e.,  active control),  or placebo, used as a
reference in a clinical trial.
CONFIDENTIALITY
Prevention of disclosure to other than authorized individuals of a sponsor's proprietary
information or of a subject's identity.
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CONTRACT
A written, dated, and signed agreement between two or more involved parties that sets
out any arrangements on delegation and distribution of tasks and obligations and if
appropriate on financial matters. The protocol may serve as the basis of a contract.
COORDINATING INVESTIGATOR
An investigator  assigned  the responsibility for  the coordination of  investigators  at
different centre’s participating in a multicentre trial.
CONTRACT RESEARCH ORGANIZATION (CRO)
A  person  or  an  organization  (commercial,  academic,  or  other)  contracted  by  the
sponsor to perform one or more of a sponsor's trial-related duties and functions
DOCUMENTATION
All records in any form (including, but not limited to, written, electronic, magnetic,
and optical records, and scans, x-rays, and electrocardiograms) that describe or record
the methods,  conduct,  and/or results  of a  trial  the factors  affecting a trial  and the
actions taken.
GOOD CLINICAL PRACTICE (GCP)
A standard  for  the  design,  conduct,  performance,  monitoring,  auditing,  recording,
analyses,  and reporting  of  clinical  trials  that  provides  assurance  that  the data  and
reported  results  are  credible  and  accurate  and  that  the  rights,  integrity  and
confidentiality of trial subjects are protected.
INSPECTION
The act  by a regulatory authority of  conducting an  official  review of  documents,
facilities,  records,  and any other resources  that  are deemed by the authority to be
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related  to  the  clinical  trial  and  that  may be located  at  the  site  of  the  trial  at  the
sponsor's  and/or  contract  research  organizations  (CRO’s)  facilities  or  at  other
establishments deemed appropriate by the regulatory authority.
INSTITUTIONAL REVIEW BOARD (IRB)
An independent body constituted of medical, scientific, and non-scientific members,
whose responsibility is to ensure the protection of the rights, safety and well-being of
human subjects involved in a trial by among other things reviewing, approving, and
providing continuing review of trial protocol and amendments and of the methods and
material  to  be  used  in  obtaining  and  documenting  informed  consent  of  the  trial
subjects.
INVESTIGATOR
A person responsible for the conduct of the clinical trial at a trial site. If  a trial is
conducted by a team of individuals at a trial site, the investigator is the responsible
leader  of  the  team  and  may  be  called  the  principal  investigator.  See  also  Sub
investigator. 
INVESTIGATOR'S BROCHURE
A compilation of the clinical and nonclinical data on the investigational product(s)
which is relevant to the study of the investigational product(s) in human subjects 
PROTOCOL
A  document  that  describes  the  objective(s),  design,  methodology,  statistical
considerations,  and  organization  of  a  trial.  The  protocol  usually  also  gives  the
background and rationale for the trial, but these could be provided in other protocol
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referenced documents. Throughout the ICH GCP Guideline the term protocol refers to
protocol and protocol amendments.
PROTOCOL AMENDMENT
A written description of a change(s) to or formal clarification of a protocol
PHARMACEUTICAL ALTERNATIVES
Medicinal  products are pharmaceutical  alternatives if they contain the same active
moiety but differ in chemical form (salt, ester, etc)
PHARMACEUTICAL EQUIVALENTS 
Products that contain the same amount of the same active substance(s) in the same
dosage form, meet the same or comparable standards 
REGULATORY AUTHORITIES 
Bodies  having  the  power  to  regulate.  In  the  ICH  GCP  guideline  the  expression
Regulatory Authorities includes the authorities that review submitted clinical data and
those that conduct inspections. These bodies are sometimes referred to as competent
authorities
SPONSOR
An individual, company, institution, or organization which takes responsibility for the
initiation, management, and/or financing of a clinical trial
STANDARD OPERATING PROCEDURES (SOPS)
Detailed, written instructions to achieve uniformity of the performance of a specific
function.
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SUBINVESTIGATOR
Any individual member of the clinical trial team designated and supervised by the
investigator at a trial site to perform critical trial-related procedures and/or to make
important trial-related decisions (e.g., associates, residents, research fellows). See also
Investigator.
SUBJECT/TRIAL SUBJECT
An  individual  who  participates  in  a  clinical  trial,  either  as  a  recipient  of  the
Investigational product(s) or as a control.
THERAPEUTIC EQUIVALENTS 
Pharmaceutically equivalent products whose effects with respect to both safety and
efficacy are essentially the same when administered.
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LITERATURE REVIEW
                       
                                
                        Review of   literature is an essential component for a worthwhile study in
any field of knowledge. It helps the investigator to gain information on what has been
done previously and to gain deeper insight into previous research problem. It  also
helps to plan and conduct the study in a systemic way. 
                  Study has been done under various divisions like gastric  emptying in
patients with non-ulcer dyspepsia, smooth muscle relaxants, QT interval prolongation
of pro arrhythmia, gastro intestinal modulator.
                                Delvaux M et.al.,(1997) has reported “Trimebutine: mechanism of
action,  effects  on  gastrointestinal  function  and  clinical  results”.[26]  The  actions  of
trimebutine [3,4,5-trimethoxybenzoic acid 2-(dimethylamino)-2-phenylbutylester] on
the gastrointestinal tract are mediated via (i) an agonist effect on peripheral mu, kappa
and delta opiate receptors and (ii) release of gastrointestinal peptides such as motilin
and  modulation  of  the  release  of  other   peptides,  including  vasoactive  intestinal
peptide,  gastrin  and  glucagon.  Trimebutine accelerates  gastric  emptying,  induces
premature phase III of the migrating motor complex in the intestine and modulates the
contractile  activity  of  the  colon.  Recently,  trimebutine  has  also  been  shown  to
decrease  reflexes  induced  by  distension  of  the  gut  lumen  in  animals  and  it  may
therefore  modulate  visceral  sensitivity.  Clinically,  trimebutine has  proved  to  be
effective in the treatment of both acute and chronic abdominal pain in patients with
functional  bowel  disorders,  especially  irritable  bowel  syndrome,  at  doses  ranging
Dept.of Pharmacology                                                               JKKMMRF College of Pharmacy29
Chapter 2                                                                                            Literature Review
from 300 to 600 mg/day. It  is also effective in children presenting with abdominal
pain.
   
                             Ayse aktas M.D et.al.,(1999)  has reported “The effect of
trimebutine maleate on gastric  emptying in patients with non-ulcer  dyspepsia”,  To
investigate the effect of trimebutine,a drug used in both hyperkinetic and hypo kinetic
motility disorders, on gastric emptying in patients with non ulcer dyspepsia having
prolonged  gastric  emptying  rates  and  to  compare  the  parameters  used  for  the
determinations of the lag period observed during the emptying of solid foods from the
stomach. Gastric emptying was measured by the radionuclide technique. 20 normal
volunteers and 43 patients with non-ulcer dyspepsia participated in the study. Radio
nuclide imaging was performed by using a solid meal labeled with Tc- tin colloid of
the patients with non –ulcer dyspepsia,20 had prolonged gastric emptying .they were
given 3 weeks of oral treatment with trimebutine maleate and had their radio nuclide
gastric  emptying  study  repeated  .treatment  with  trimebutine maleate  resulted  in
reduction  in  duration  of  the  lag  period  and  less  retention  of  food  and  100
minutes(P<0.0005).after treatment with trimebutine maleate ,no significant difference
has been observed in the mean symptom score of  patients with prolonged gastric
emptying. Among the parameters used for the determination, of the lag period, lag
period determined by a mathematical equation (TLAG) has been found to be longer
than the lag period determined by visual inspection of the images (VLAG) and there
was correlation between the two parameters when the lag time was short.
                            
                              Poynard T et.al., (2001) has reported “Meta analysis of smooth
muscle relaxants in the treatment of irritable bowel syndrome” To up date previous
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overview of placebo controlled double blind trails assessing the efficacy and tolerance
of  smooth  muscle  relaxants  in  irritable  bowel  syndrome  method:  a  total  of  23
randomized  clinical  trails  were  selected  for  meta  analysis  of  their  efficacy  and
tolerance.  Six  drugs  were  analysed  :  climetropium bromide  (five  trails),  hyosine
butyle  bromide (three  trails),Mebeverine  (five  trails)  otilium bromide (four  trails),
pinaverium bromide(two trails), Trimebutine (four trails). The total number of patients
included was 1888,  of  which 945 received  an active drug and 943 a placebo.  As
resulted the mean percentage of patients with global improvements was 38% in the
placebo  group  (n=925)  and  56%  in  the  myorelaxnt  group  (n=927)  in  favour  of
myorelaxants with a mean odds ratio of 2.13 P<0.001 (95% CI : 1.77 -2.58) and a
mean risk difference  of  22% P<0.001(95%CI:  13-32%) the percentage  of  patients
with  pain  improvement  was   41%  in  the  placebo  group  (n=568)  and  53%  in
myorelaxant group (n=567). Odds ratio 1.65, P<0.001 (95% CI : 1.30-2.10) and risk
difference 18%, P<0.001  (95% CI: 7-28%). There was no significant difference for
adverse events .concludely myorelaxants are superior to placebo in the management
of the irritable bowel syndrome.
                              Miuria Y et.al.,(2005)   has reported as “studies of metabolic
pathways  of  trimebutine by  simultaneous  administration  of  trimebutine and  its
deuterium-labeled  metabolite.”  Trimebutine maleate  (I),  (+-)-2-dimethylamino-2-
phenylbutyl  3,4,5-trimethoxybenzoate  hydrogen  maleate,  and  a  deuterium-labeled
sample  of  its  hydrolyzed  metabolite,  2-dimethylamino-2-phenylbutanol-d3  (II-d3),
were simultaneously administered to experimental animals at an oral dose of 10 or 50
mumol/kg, and distribution ratios of the two alternative initial metabolic steps, i.e.,
ester hydrolysis and N-demethylation, were estimated by determining the composition
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of  the  urinary  alcohol-moiety  metabolites,  II,  and  its  mono-  and  di-demethylated
metabolites, III and IV, by GC/MS. In dogs, the order of quantities of the metabolites
from II-d3 was II much greater than III much greater than IV, showing predominance
of conjugation over  N-demethylation.  However,  this  order  was reversed  when the
amounts of the metabolites from I were compared, indicating that I was preferentially
metabolized by N-demethylation followed by ester hydrolysis and conjugation in this
order. In rats, a considerable proportion of I was presumed to be metabolized by ester
hydrolysis  before  N-demethylation.  In  in-vitro experiments  employing  the  liver
microsomes and homogenates of liver and small intestine from rats and dogs, it was
found that both ester-hydrolizing and N-demethylating activities were higher in rats
than in dogs, and the conjugating activity was higher in dogs than in rats. It was also
found that I,  having a high lipophilicity,  was more susceptible to N-demethylation
than less lipophilic II. These results from the in-vitro experiments could account for
the species differences in the distribution ratio of the metabolic pathways of I in vivo.
                             
                               Patel S.M.et.al.,(2005)  has reported on “The placebo effect in
irritable  bowel  syndrome  trials:  a  meta-analysis”[24],  [25]  .Despite  the  apparent  high
placebo  response  rate  in  Randomized  placebo-controlled trials (RCT) of patients
with irritable bowel syndrome(IBS),  little is  known   about   the   variability   and
predictors of this response. To describe the magnitude of response in   placebo   arms
of IBS clinical  trials and   to  identify which    factors  predict  the  variability   of the
placebo  response. performed a  meta-analysis  of  published  English language,  RCT
with 20 or more IBS patients who were treated for at least 2 weeks. This analysis is
limited    to  studies   that   assessed    global   response (improvement in overall
symptoms).The   variables  considered  as  potential  placebo  modifiers   were  study
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design,  study  duration,  use  of  a  run-in  phase, Jadad score, entry criteria, number
of office visits, number of office  visits/study  duration,  use  of  diagnostic  testing,
gender, age and type of medication studied Forty-five  placebo-controlled  RCTs  met
the inclusion  criteria.  The  placebo  response  ranged  from16.0  to  71.4%  with  a
population-weighted   average   of40.2%,     95%   CI   (35.9–44.4).   Significant
associations with  lower  placebo  response  rates  were  fulfilment  of the  Rome
criteria  for  study  entry  (P = 0.049)  and  an increased number of office visits (P
=0.026). Placebo effects in IBS clinical trials measuring a global outcome are highly
variable .Entry criteria and numbers of office visits are significant predictors of the
placebo response.  More stringent  entry criteria  and an increased  number of  office
visits appear to in dependently decrease the placebo response.
                               Schiariti. M et.al., (2009)  has reported on “QT Interval
Prolongation and Atypical Proarrhythmia:Monomorphic Ventricular Tachycardia with
Trimebutine”[17],[18],[19]A   59-year old   woman   was   admitted   at   emergency   for
palpitation   and   dizziness.  Medication   history showed  Trimebutine    450   mg
daily,   because   of   meteorism,   increased   to   450   mg   TID   a   week   earlier.
At   admittance,   sustained monomorphic ventricular tachycardia was interrupted by
100 mg intravenous lidocaine and a largely prolonged QTc (523 ± 12 ms) was seen.
Discontinuation  of  Trimebutine  achieved  normalisation  of  QTc  (420  ±  10  ms,
p<0.001). This is the first report in man to illustrate a probable proarrhythmic action
of  trimebutine. A weak inhibitory effect on both rapid and slow components of the
delayed rectifier in guinea-pig ventricular myocytes calls for further investigations in
human  myocardial  tissues.  Trimebutine  inhibition  of  Na+  and  Ca++  channels  in
cardiac  tissues  of  rabbits  and  guinea-pigs  also  call  for  further  studies  in  human
myocardial tissues.
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                              Hyun-thai lee et.al., (2011) has reported as “Trimebutine as a
modulator  of gastrointestinal  motility”  Trimebutine has been used for treatment of
both hypermotility and hypomotility disorders of the gastrointestinal (GI) tract, such
as  irritable  bowel  syndrome.  In  this  issue,  Tan  et  al.  (2011)  examined  the
concentration-dependent dual effects of trimebutine on colonic motility in guinea pig.
The authors suggested that trimebutine attenuated colonic motility mainly through the
inhibition  of  L-type  Ca2+ channels  at  higher  concentrations,  whereas,  at  lower
concentrations,  it  depolarized  membrane  potentials  by  reducing  BKca currents,
resulting  in  the  enhancement  of  the  muscle  contractions.  Trimebutine might  be  a
plausible  modulator  of  GI  motility,  which  gives  an  insight  in  developing  new
prokinetic  agents.  Further  studies  to  elucidate  the  effects  of  trimebutine on  the
interstitial cells of Cajal, the pacemaker in GI muscles would promote the therapeutic
benefits as a GI modulator.
                    
                               Kountouras J, et.al.,(2012)has reported on “Trimebutine as a
potential antimicrobial agent:  a preliminary  in-vitro approach”.[20],[21],[22]  .The aim of
this  preliminary  study  was  to  investigate  the  in-vitro effect  of  “non-antibiotic”
trimebutine against   reference strains Staphylococcus aureus  ATCC 29213, ATCC
25923, Escherichia coli ATCC 25922, ATCC 35218, Pseudomonas aeruginosa ATCC
27853 and   Enterococcus faecalis  ATCC 29212; microbiota  that  are potentially
involved  in  the  patho  physiology  of  post-infectious  functional  gastrointestinal
disorders.  Trimebutine activity  was  assessed  by  the  broth  micro  dilution  method
according  to  Clinical  and  Laboratory  Standards  Institute  recommendations  against
reference strains S. aureus ATCC 29213 and ATCC 25923, E. coli  ATCC 25922 and
ATCC 35218, P. aeruginosa ATCC 27853 and E. faecalis ATCC 29212. Bactericidal
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activity of the compound was determined by spreading a 10 µL aliquot on Mueller-
Hinton agar from each dilution showing non-visible growth. All tests were carried out
in triplicate.  Trimebutine was active against  all strains tested presenting with MIC
ranging from 1024 to 4000 mg/L. MIC  and MBC were similar for E. coli ATCC
25922 and P. aeruginosa ATCC 27853 whereas for Gram-positive isolates  and E. coli
ATCC  35218  the  MBC  was  higher.  Concludely  they  demonstrated  the  in-vitro
bacteriostatic/bactericidal    activity  of  trimebutine    against   bacteria frequently
colonizing the gastrointestinal tract and potentially involved in human gastrointestinal
infections that might trigger post-infectious functional gastrointestinal disorders.
                 
                                                       DRUG PROFILE
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NAME            :    Trimebutine  
CHEMICAL NAME    :   2-dimethyl amino-2-phenyl-butyl 3,4,5-trimethoxybenzoate
STRUCTURAL FORMULA:
EMPIRICAL FORMULA     :      C22H29NO5
MOLECULAR WEIGHT      :      387.5 
CATEGORY                         :      lower gastro intestinal tract motility regulator
SUB CLASS                          :      non-competitive spasmolytic agent 
PHYSICAL PROPERTIES      :         Appearance    -   white to off-white powder
                                                        Solubility       - sparingly soluble in water
                                                         Melting point    - 128○- 134○C
              USE             :                      To Treat spastic colon, Irritable Bowel Syndrome.
CLINICAL PHARMACOLOGY:
MECHANISM OF ACTION
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The  mode  of  actions  of  trimebutine [3,4,5-trimethoxybenzoic  acid  2-(dimethyl
amino)-2-phenylbutylester] on the gastrointestinal tract are mediated via (i) an agonist
Ɣeffect on peripheral mu (µ), kappa and delta ( ) opiate receptors and (ii) release of
gastrointestinal  peptides  such  as  motilin  and  modulation  of  the  release  of  other
peptides, including vasoactive intestinal peptide, gastrin and glucagon.  Trimebutine
accelerates  gastric  emptying,  induces  premature  phase  III  of  the  migrating  motor
complex in the intestine and modulates the contractile activity of the colon.[27],[28]
Trimebutine
                      Induces
Migrating motor complex in intestine
                      Modulates                                                               
Contractile activity of colon
                      Accelerates
Gastric Emptying
FIGURE 2: The above figure shows the mechanism of action of Trimebutine .
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Mediation of gastro intestinal tract:
                                                                         
                                                                                                 
via                                                  via                       
FIGURE 3: The above figures shows colon and the mediation of GIT 
PHARMACOKINETICS
Absorption
Trimebutine maleate or its free base is rapidly absorbed after oral administration. Peak
plasma concentrations of radioactivity were observed within one hour in man and rat
and within 2-4 hours in the dog. Plasma radioactivity in man indicated a kinetic model
with central  and peripheral compartments and a mean distribution half-life of 0.66
hour.
Distribution
Tissue distribution studies showed high concentration of the radio labeled drug in the
stomach and the intestinal walls of rat and in the major organs of metabolism and
Dept.of Pharmacology                                                               JKKMMRF College of Pharmacy38
Agonistic effect on peripheral mu (µ) 
Ɣ ƙdelta ( ) kappa ( ) opiate receptor 
Release of gastro intestinal peptides 
like motilin &modulation of other 
peptides, gastrin, glucagon
Gastro intestinal tract mediation
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excretion in mice. Placental transfer without teratogenic effect was observed in the
rat. Protein-binding was less than 5% in vivo (rat plasma) and in vitro (bovine serum
albumin).
Metabolism
Trimebutine undergoes  N-demethylation  process  which  is  an oxidative reaction  of
phase I  (N-dealkylation),  here  methyl  groups  are  directly  attached to  the nitrogen
atom which yields amines and amides after metabolized. However,  two alternative
initial metabolic steps, i.e., ester hydrolysis and N-demethylation which gives mono-
and di-demethylated metabolites, 
Trimebutine is  extensively  metabolised,  although  the  metabolites  appear  to  be
pharmacologically inactive in man. 
Elimination
Urine was the main route of elimination in all species while a small percentage (5-
12%) of radioactivity was detected in the faeces. The plasma half-life of Trimebutine
was short, but the elimination half-life of radioactivity was approximately 10-12 hours
in  man  and  rat.  In  the  rat,  an  entero-hepatic  circulation  was  also  demonstrated.
Extensive metabolism of the parent compound was indicated since less than 2.4% of
the urinary radioactivity was found as unchanged drug in all species
Drug Interactions
Animal  studies  have  shown that  trimebutine maleate  increases  the  duration  of  d-
tubocurarine-induced curarization.   No other drug interactions  have been observed
during clinical trials or otherwise reported.
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Adverse drug reactions
In clinical studies, adverse effects of mild to moderate nature occurred in 7% of the
patients treated with Modulon (trimebutine maleate).  No single side effect occurred
in more than 1.8% of the patients and some of these might have been related to the
patient’s condition rather than the medication. The commonly reported adverse effects
are as follows: 
 a) Gastrointestinal: Dry mouth, foul taste, diarrhea, dyspepsia, epigastric pain, nausea
and constipation were reported in total of 3.1% of the patient population;
 b)  CNS:  Drowsiness,  fatigue,  dizziness,  hot/cold  sensations  and  headaches  were
reported in 3.3%; 
c) Allergic reactions: Rash in 0.4% of the patients; and
 d) Miscellaneous effects: Menstrual problems, painful enlargement of breast, anxiety,
urine retention and slight deafness were also infrequently reported.
Dosage and administration
Trimebutine is available in the brand name of Modulon, Debridat, digedrat : 
Tablets: Digedrate® 200 mg: each white, round, biconvex tablet, bisected on one side
contains 200 mg of trimebutine maleate per tablet; bottles of 100.
The  adult  recommended  dose  is  up  to  600  mg  daily  in  divided  doses.   It  is
administered as one 200 mg tablet three times daily before meals.
Contraindication 
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Trimebutine  maleate  is  contraindicated  in  patients  with  known  hypersensitivity  to
trimebutine maleate or any of the excipients. Although teratological studies have not
shown any drug related adverse effects on the course and outcome of pregnancy in
laboratory  animals  by  both  oral  and  parenteral  routes,  the  use  of  Modulon
(trimebutine maleate) in pregnant women is not recommended.
 Children: Not recommended for use in children under 12 years of age.
DISEASE SPECIFIC LITERATURE REVIEW
IRRITABLE BOWEL SYNDROME
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INTRODUCTION
                                 Irritable Bowel Syndrome (IBS) is one of the most common
ailments of the bowel (intestines) and affects an estimated 15% of people in the US.
The term, irritable bowel, is not a particularly accurate one since it implies that the
bowel is responding irritably to normal stimuli, and this may or may not be the case.
The several terms used for IBS, including spastic colon, spastic colitis, and mucous
colitis, attest to the difficulty of getting a descriptive handle on the ailment. Moreover,
each of the other names is itself as problematic as the term IBS.
Irritable  Bowel  Syndrome (IBS or spastic  colon)  is  a  symptom-based  diagnosis
characterized by chronic abdominal pain discomfort, bloating, and alteration of bowel
habits. As functional gastro intestinal disorder (FGID),  IBS has no known organic
cause.[1]
CLASSIFICATION 
IBS can be classified as 3 sub classes  
a) Diarrhea-predominant (IBS-D), 
b) Constipation-predominant (IBS-C), or with 
c) Alternating stool pattern (IBS-A) or pain-predominant.[51]In some individuals,
 IBS may have an acute onset and develop after an infectious illness characterized by
two or more of the following: fever, vomiting, diarrhea, or positive stool culture. This
post-infective syndrome has consequently been termed "post-infectious IBS" (IBS-
PI).
ETIOLOGY 
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The cause of IBS is unknown; several hypotheses have been proposed. The risk of
developing IBS increases sixfold after acute gastrointestinal infection. Post infection,
further risk factors are young age, prolonged fever, anxiety, and depression. Theories
of the cause of IBS include abnormal input from intestinal sensory nerves, abnormal
processing  of  input  from  the  sensory  nerves,  and  abnormal  stimulation  of  the
intestines by the motor nerves. Causes of IBS usually stress. Genetic tendency, drug
addiction, other infections and some food sensitivity food allergic reactions all these
may leads to abnormal stimulation of the intestinal motility. The causes of IBS are
summarized below:
Figure 4 : shows  causes of Inflammatory Bowel Syndrome
PATHO PHYSIOLOGY 
A  system  of  nerves  runs  the  entire  length  of  the  gastrointestinal  tract  from  the
esophagus to the anus in the muscular walls of the organs. These nerves communicate
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with other nerves that travel to and from the spinal cord. Nerves within the spinal
cord, in turn, travel to and from the brain. (As an organ system, the gastrointestinal
tract  is  exceeded  only  by  the  spinal  cord  and  brain  in  the  numbers  of  nerves  it
contains.) Thus, the abnormal function of the nervous system in IBS may occur in a
gastrointestinal muscular organ, the spinal cord, or the brain. "Brain-gut response to
stress  and  cholinergic  stimulation  in  IBS"  The  nervous  system  that  controls  the
gastrointestinal organs, as with most other organs, contains both sensory and motor
nerves. The sensory nerves continuously sense what is happening within the organ
and relay this information to nerves in the organ's wall. From there, information is
relayed to the spinal cord and brain. The information is received and processed in the
organ's wall, the spinal cord, or the brain. Then, based on this sensory input and the
way the input is processed, commands (responses) are sent to the organ through the
motor  nerves.  Two  of  the  most  common  motor  responses  in  the  intestine  are
contraction or relaxation of  the muscle  of  the organ and secretion of  fluid and/or
mucus into the organ. the role of brain-gut "axis" appeared in the 1990s, such as the
study "Brain-gut response to stress and cholinergic stimulation in IBS"
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               Figure 5: shows the pathophysiology of Inflammatory Bowel Syndrome 
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Figure 6: shows the differences of normal colon and spastic colon 
SIGNS AND SYMPTOMS 
The primary symptoms of IBS are abdominal pain or discomfort in association with
frequent diarrhea or constipation and a change in bowel habits.[47]There may also be
urgency  for  bowel  movements,  a  feeling  of  incomplete  evacuation  (tenesmus),
bloating,  or abdominal  distension[24]In  some  cases,  the  symptoms  are  relieved
by bowel  movements.[7] People with IBS,  more commonly than others,  have gastro
esophageal  reflux,  symptoms  relating  to  the genitourinary  system, chronic  fatigue
syndrome, fibromyalgia, headache, backache and  psychiatric  symptoms  such
as depression and anxiety.[48][49] Some studies indicate that up to 60% of persons with
IBS also have a psychological disorder, typically anxiety or depression.[50]
Dept.of Pharmacology                                                               JKKMMRF College of Pharmacy46
Chapter 2                                                                                            Literature Review
DIAGNOSIS
There is  no specific  laboratory or imaging test  that  can be performed to diagnose
irritable bowel syndrome. Investigations are performed to exclude other conditions:
Stool microscopy and culture (to exclude infectious conditions)
• Blood  tests: Full  blood  examination, Liver  function  tests, Erythrocyte
sedimentation rate, serological testing for coeliac disease
• Abdominal ultrasound (to exclude gallstones and other biliary tract diseases)
• Endoscopy and  biopsies  (to  exclude  peptic  ulcer  disease,  coeliac  disease,
inflammatory bowel disease, malignancies)
• Hydrogen breath testing (to exclude fructose and lactose malabsorption)
TREATMENT
 A number of treatments have been found to be better than placebo, including fiber,
antispasmodics, and peppermint oil
Proper diet plan can reduce symptoms in functional GI disorders such as IBS by 60-
80%
Drugs classifications: 
 Absorbants   -     Ispaghula,  Psyllium
                                         Methyl cellulose.
 Anti secretory  -   Sulfasalazine mesalazine, Olsalazine 
                             Balsalazine, Bismuth sub salicylate, Racecodrotil 
 Corticosteroids – Prednisolone. 
 Immunosuppressants – Azathioprine , Methotrexate, Cyclosporine, 
                                      Infliximab 
 Anti motility – Codeine, diphenoxylate , loperamide . 
 Spasmolytic agents - met chlorpramide. 
 GIT regulators   -    Trimebutine,
 Seratonergic drugs – prucalopride 
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 Anti inflammatory  agents and mast cell stabilizers –ketotifin
 Antibiotics  -   rifaximin 
 Probiotics 
 Other new drugs  - Furiox, 
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OBJECTIVES OF STUDY
PRIMARY:
                    To investigate the bioequivalence of  Trimebutine 200 mg capsules
(Product  Test).and  Digedrat®  (Product  Reference)  200 mg capsules  in  48  healthy,
adult, human, male and non-pregnant female subjects under fasting conditions.
.
SECONDARY:
                           To  monitor adverse events and ensure safety of the subjects.
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Plan of work:
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy50
Chapter 4                                                                                Materials and Methods 
MATERIALS AND METHODS
STUDY DESIGN:                   
An open label, randomized, two treatment, two sequences, two period, single dose,
crossover, oral bioequivalence study under fasting conditions
.
 
STUDY CENTRE:
Azidus laboratories Ltd., Rathnamangalam, Vandalur, Chennai-48.
STUDY POPULATION:
                    Healthy, adult, human, male and non-pregnant female volunteers 
SAMPLE SIZE:
                   48 subjects (24 male and 24 non-pregnant female) 
STUDY TYPE:
Fasting study.
NUMBER OF PERIODS: 
            02
STUDY DURATION:
        09days 
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CLINICAL PROCEDURE:
STUDY DESIGN 
An open label, balanced, randomized, two treatment, two sequence, two period, single
dose, cross over, oral bioequivalence study of Trimebutine 200 mg capsules (Test)and
Digedrat®  (Product Reference) 200 mg capsules in 48  healthy, adult, human, male
and non-pregnant female subjects under fasting conditions. 
Open label: It is a condition where both the physician and the participating subjects
know about the treatment administered.
Balanced: In the randomization schedule the blocks will be balanced.
Two treatments: One test product and one reference product.
Two sequence: One sequence is TR and the other RT.
R=Reference;    T=Test
Single dose: Trimebutine 200 mg capsules.
Number of  subjects:  48 Healthy adult  human volunteers  will  be included in  the
study.
Washout period:  At least 05 days  will be given as the wash out period for each
dosing.
Blinding:  This study is an open labeled study the subjects and the investigator will
not be blinded towards the identity of the study treatments.
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Test and Reference products
Test(T): Trimebutine 200 mg capsules 
Reference(R): Digedrat® 200 mg capsules
Receipt and storage of Investigational products
The sponsor supplied sufficient quantity of the investigational products to the testing
facility along with their certificate of analysis (COA) for conduct of the study. The
test  and  reference  products   supplied  in  sealed  packages  or  stripes  labeled  with
product name, strength, Number of dosage units, Manufacturer name, Lot number or
Batch number, Expiration date and storage conditions.
After receipt of the investigational products, test and reference products has kept in
separate storage box (labeled with project NO., Name of IP, Type of IP, Batch NO,
and  Expiry  date  and  storage  conditions)  and  stored  in  Refrigerator  located  in
pharmacy.
Upon completion or termination of the study, the unused investigational products will
be returned to sponsor.
Accountability of the Investigational products
The  record  of  the  total  medications  received  and  the  quantity  of  drug  used  and
retained with or returning to the sponsor will be maintained in the pharmacy.
Selection and with drawl of subjects
Subject screening
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Each subject had undergone screening procedure for health assessment which consists
of  a  complete  medical  history,  physical  examination  with  vital  signs,  clinical
laboratory evaluations,12-lead ECG and chest x-ray PA view (if not done in the past 6
months or if clinically indicated).The physical  examination findings,  ECG and the
laboratory tests can be considered valid maximum upto 28 days prior to the dosing in
first period of the study.
Clinical laboratory tests 
Screening Laboratory tests
Biochemistry Hematology
Urine (routine
analysis)
Serology Others 
• Blood Sugar-Random
• Serum Urea
• Creatinine
• Total Cholesterol
•  Triglycerides 
• Serum Bilirubin (Total)
• Serum Bilirubin (Direct)
• Serum  Bilirubin
(Indirect)
• Uric acid 
• ALT
• AST
• Alkaline Phosphatase
• Total Protein
• Total  W.B.C.
count 
• Differential
leukocyte
count
• Total  R.B.C.
count
• Hemoglobin
• Haematocrit
(PCV)
• Platelets count
• ESR   (1st
Hour)
• Blood
Grouping  &
• Turbidity
• Colour
• RBCs
• Bilirubin 
• Urobilinogen
• Ketone
• Protein 
• Nitrite
• Glucose 
• pH 
• Specific
Gravity
• Microscopic
Examination
• HIV 1 & 2 
• Hepatitis  B
surface
antigen
Hepatitis  C
antibody 
• Syphilis  
• Chest  X  ray
PA view 
• ECG  in  12
leads 
• Urine  drugs
of abuse*
• Alcohol
breath
analysis*
• Urine
pregnancy
test(in  case
of females)*
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• Albumin
• Globulin
• A/G Ratio
• LDH
• Gamma  Glutamyl
Transferase
• Sodium
• Potassium
• Chloride
• Calcium 
• Serum pregnancy  test(in
case of females)
Rh Typing
(Leucocytes
&  Epithelial
cells)
INCLUSION CRITERIA 
Subjects must fulfill all of the following criteria to be considered for inclusion into
this study:
 Gender: Healthy male and/or non-pregnant female volunteers.
 Age:  20 - 45 yrs (both years inclusive) 
 Willing  to  give  informed  written  consent  and  comply  with  the  study
requirements.
 Female volunteers practicing an acceptable method of birth control as judged
by  the  investigator(s),  such  as  condom  with  spermicide,  diaphragm  with
spermicide, intrauterine device (IUD), or abstinence throughout the duration
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of the study; or of postmenopausal (no menses) status of at least 1 year; or
surgically  sterile  (bilateral  tubal  ligation,  bilateral  oophorectomy,  or
hysterectomy). 
 Subject should be able to communicate effectively.
 Non-smokers.
 Body Mass Index (BMI) 18.50-24.90 Kg/m2 for males, 18.50-30.00 Kg/m2 for
females, and body weight not less than 50 kg.
 Healthy  individuals  as  evaluated  by  personal  history,  medical  history  and
general clinical examination.
 Vital parameters – 
BP: 100 – 139 mmHg systolic and   60 – 89 mmHg diastolic. 
Pulse rate: 60 – 100 / min. 
Oral temperature: between 97.8˚ F and 99.0 ˚ F.  
 Respiratory rate: 14-18/min.
 Normal biochemical, hematological and urinary parameters.
 Normal Chest X - ray PA view & ECG in 12 leads.
 Negative for HIV 1 & 2, Hepatitis B, Hepatitis C, and Syphilis tests.
 Negative  urine  test  for  drugs  of  abuse  for  morphine,  barbiturates,
benzodiazepines, amphetamine, THC & cocaine (to be performed on the day
of check in during each period). 
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 Negative  serum  test  for  pregnancy  during  screening  and  Negative  urine
pregnancy  test  on  the  day  of  check  in  during  each  period  (for  female
volunteers).
 Negative  alcohol  breath  analysis  (to  be  performed  on the day of  check  in
during each period)
EXCLUSION CRITERIA 
. The subjects will be excluded based on the following criteria:
 Subject incapable of understanding the informed consent. 
 History of any major surgical procedure in the past 3 months. 
 History of diabetes mellitus, tuberculosis and systemic hypertension. 
 History  suggestive  of  cardiac,  gastrointestinal,  respiratory,  hepatic,  renal,
endocrine,  neurological,  metabolic,  psychiatric  or  hematological  systems,
judged to be clinically significant. 
 History of dysphasia.
 History of any medical disorder  that is of significance in the investigator’s
opinion. 
 Present or past history of smoking, alcohol intake or drug abuse. 
 History of consumption of tobacco containing products. 
 History of hypersensitivity to  Trimebutine and related drugs or excipients in
the formulation (if the excipients are known).  
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 History of allergy to vegetables and / or food substances and / or any other
manifestations suggestive of hypersensitivity reactions.  
 Present or past history of intake of drugs* which potentially modify kinetics /
dynamics  of  Trimebutine  or  any  other  medication  judged  to  be  clinically
significant by the investigator.     
 Consumption of grapefruit / its products within 48 hours prior to the start of
study.  
 Intake  of  any prescription  drug within 14 days  or  over-the counter  (OTC)
drugs within 7 days prior to study and / or intake of any drug* in the past that
could affect the kinetics or dynamics of Trimebutine in view of investigator.    
 Subject with clinically significant abnormal values of laboratory parameters. 
 Pregnant, Lactating Females.
 Subject  who had  participated  in  any other  clinical  study during  the  last  6
months. 
 Subject who had bled in the past 6 months from the date of start of study either
for blood donation or for any other reason.  
 History of habituation to coffee, tea or other xanthine containing products and
inability to
 Withhold the intake during the - in house - stay. 
 Drugs that can potentially affect the hepatic metabolism* of other drugs are as 
listed below (not limited to the list, though)
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*Hepatic  microsomal  enzyme  inducers  (which  can  reduce  the  systemic
bioavailability):-  Barbiturates,  Carbamazepine,  Ethanol  (chronic),  Inhalational
anaesthetics, Griseofulvin, Phenytoin, Primidone, Rifampicin.
CRITERIA  FOR  DISCONTINUATION  OR  WITHDRAWAL  FROM  THE
STUDY.
 Subjects  will  be  withdrawn  or  may  discontinue  from  the  study  for  any  of  the
following  reasons.  In  case  of  withdrawal,  the  details  must  be  documented  in  the
appropriate Case Report Form (CRF).
 The subject withdraws consent.
 Development of intolerable adverse event.
 Emesis occurred at or before two times reported median Tmax and/or 
significant diarrhea, in any period.
 Development  of  an inter  current  illness  or  condition for  which the subject
requires concomitant medications which may interfere with the kinetics of the
study medication.
 Discovery that the subject  entered the study in violation of the protocol or
occurrence of a significant protocol violation during the study.
 The  investigator  feels  that  in  the  best  interest  of  the  subject’s  health,  the
subject is to be withdrawn from the trial. 
 Data not known before starting the trial become available and raise concern
about the safety of the study drug so that continuation would pose potential
risk to any particular subject.
STUDY PROCEDURE:
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           The study was conducted after obtaining approval from the Independent Ethics
Committee (IEC). Prospective volunteers were explained about the study procedure
and purpose. After obtaining written informed consent from willing participants, they
were  subjected  to  screening  by  History,  Clinical  examination  and  laboratory
investigations. 
HOUSING:
           In all periods, the subjects were housed in the clinical facility, minimum 12
hours prior  to dosing until  48 hours  post  dose.  All  subjects were  maintained in a
fasting state for a minimum 8 hours prior to dosing. 
 Subjects were  admitted at  least  12 hours before the proposed time of drug
administration.
 After drug administration, subjects had to stay for at least 48 hrs. The duration
of  stay  in  each  period  (from  subject  check-in  to  check-out)  was  60  hrs,
spreading over a period of 4 days.
DIET& WATER:
 Being a fasting study, subjects were not served any breakfast on the day of
dosing.
 Subjects received standard food, approximately at 4, 8 and 12,24,28,32 hours
post-dose for lunch, snacks, dinner, Breakfast, lunch and snacks respectively.
 During the study, meal plans were identical for all the subjects.
 RANDOMIZATION: 
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Study subjects  received  any of  the two investigational  (test/reference)  products  in
each of the study periods. The order of receiving the test and reference product for
each  subject  was  according  to  the  randomization  schedule.  The  randomization
schedule was generated by using SAS®.
Each study subject were randomly assigned to one of the following dosing sequences.
                                
Period I Period II
Sequence I             T R
Sequence II R T
DISPENSING
The designated study personnel dispensed a quantity of the test and reference product
a day before dosing in each period of the study. The doses transferred to the drug
dispensing sachets  as randomization schedule  and properly  labeled with the study
number, randomization code and period.
PERIOD I:  
Pre- dosing day:
 The subjects enrolled were instructed to come one day prior to the study
day for admission.
 On admission, the vital signs were recorded.
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 Dinner was provided and the subjects fasted overnight for at least 10 hours
prior to dosing.
  Study day:
 7  AM: An intravenous  cannula  was  inserted in  forearm vein for  blood
collection  and  pre-dose  blood  sample  was  collected  for  estimating  the
baseline biochemical parameters .vital signs were recorded.
 8 AM: Dosing  was  done (with 2  mts  interval  for  each subject)  as  per
randomization schedule. One tablet of  Trimebutine 200 mg capsule was
administered with 200 ml of water under direct observation .Dosing were
done  4  stations  (from S1  to  S12  in  Ist  station  ,  S13  to  S24  in  II  nd
station ,S25 to S36 in IIIrd station, S37 to S48 IV th station)
 The  subjects  were  dosed  in  sitting  posture  and  they  remained  in  erect
posture for four hours.
 They were not permitted to drink water for one hour prior to dosing and
one  hour  post  dosing  .At  all  other  times,  drinking  water  was  made
available.
 Subjects were instructed to report if they had any side effects.
 A total of 22 blood samples (each 5ml) were collected from each subject at
specific time points.
 Vital signs were recorded at .00, 04.00, 08.00, 12.00 and 24.00hours post-
dose.
 The  subjects  were  closely  monitored  for  the  adverse  events  of
Trimebutine.
 At the end of 48 hours, the volunteers were discharged.
 WASH OUT PERIOD
 The subjects were asked to come again for admission after a 5-days wash
out period 
PERIOD II:
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      Pre dosing day: 
 The subjects enrolled were instructed to come one day prior to the study
day for admission.
 On admission, the vital signs were recorded.
 Dinner was provided and the subjects fasted overnight for at least 10 hours
prior to dosing.
      Study day:
 7  AM: An intravenous  cannula  was  inserted in  forearm vein for  blood
collection  and  pre-dose  blood  sample  was  collected  for  estimating  the
baseline biochemical parameters .vital signs were recorded.
 8 AM: Dosing  was  done (with 2  mts  interval  for  each subject)  as  per
randomization schedule. One tablet of  Trimebutine 200 mg capsule was
administered with 200 ml of water under direct observation .Dosing were
done  4  stations  (from S1  to  S12  in  Ist  station  ,  S13  to  S24  in  II  nd
station ,S25 to S36 in IIIrd station,S37 to S48 in IV th station ).
 The remaining procedures were followed as same in period I.
 At the end of 48, hour’s volunteers were discharged.
 After completion of the study, blood samples were collected for post drug
analysis to confirm that the drug has been eliminated completely from the
physiological system.
 The laboratory post study values were compared with pre-study laboratory
test values .if any clinically significant deviations were seen, the subjects
were followed up and appropriate medical care provided.
DRUG ADMINISTRATION:
                  A single oral dose of test or reference product was administered to study
subjects with 2 minutes gap between each subject in all the two periods  in sitting
posture at  fixed time points with 200 ml of  water  at  ambient temperature in each
period.  The  order  of  receiving  test  and  reference  products  will  be  as  per
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randomization schedule. This activity will be followed by a mouth check to assess
compliance to dosing.
POSTURAL RESTRICTIONS:
                  Subjects will be administered with study medications in sitting posture. 
Subjects will remain upright (sitting) for the first 04 hrs post dose except for any
procedural reason or when the subject experienced the adverse event or in case of any
natural exigency.
No exercise or strenuous physical activities are permitted during the in-house stay.
METHODS OF BLOOD SAMPLE COLLECTION:
Before dosing:
            Blood samples were collected through an indwelling cannula placed in
forearm vein. If there was difficulty in obtaining through intravenous cannula, blood
samples were obtained by direct venous puncture.
         While  collecting  blood  sample,  after  insertion  of  the  cannula  and  after
withdrawal of every sample of blood, 0.5 ml of heparinised saline (10 IU/ml) was
injected to maintain the potency of  cannula.  After discarding the initial  0.5 ml of
blood, the required volume of  blood was collected.  Blood samples were  collected
using pre-labeled vials containing K3 EDTA.
In  each period 22 samples  were  collected  from each  subject  as  per  the following
schedule. The pre-dose samples will be collected within 01 hour prior to drug dosing.
After dosing:
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               The post-dose samples were  collected at 00.17, 00.33, 00.50, 00.67, 00.83,
01.00, 01.25, 01.50, 01.75, 02.00, 02.33, 02.67, 03.00, 04.00, 06.00, 08.00, 12.00,
18.00, 24.00, 36.00 and 48.00 hours post dose  (Total of 22 samples - 5 mL each).  All
22 samples will be collected as in-house samples.
The total volume of blood draw from each subject during the study will not exceed
258.0 mL.
[22x5mLx2  =  220  mL]  +  [0.5  mL  discarded  for  first  22  in-house  blood  draws
22x0.5mLx2 = 22 mL] + [screening =10 mL] + [post study safety evaluation = 6 mL]
= 258.0 mL.
SAMPLE STORAGE
            After collection, blood samples were centrifuged at 4000 rpm for 10 minutes
at 4°C ± 2°C to separate plasma. Following centrifugation, plasma will be separated
into two aliquots the first aliquot will have 1.5 ml of plasma and the second aliquot,
the remaining plasma stored  at  -20°C.  After  completion of  the  study,  the  plasma
samples of two periods were transferred to the Bioanalytical department for analysis.
While transferring the samples,  adequate measures  were taken for  maintaining the
temperature and integrity of samples.
SAFETY ASSESSMENT
In  each period, vital signs measurement and subject well being assessment will be
done during subject check-in and at 00.00 hrs (pre dose) and at 02.00, 04.00, 08.00,
12.00, 24.00 hours post-dose and during check-out. If 00.00 hours vitals found to be
abnormal, decision will be taken by the Principal Investigator regarding exclusion of
the subject from the study.
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Post study procedure:
                Following tests were performed at the end of period II
1. Hematology—        Hemoglobin in %, Platelet Count,PCV.
2. Liver functions—   Serum Glutamate Oxaloacetate Transaminase,
                                   Serum Glutamate Pyruvate Transaminase
            3. Serum Chemistry--Random Blood Sugar, Urea, Creatinine. Serum             
                                                     Pregnancy  test.
              4.others --ECG 
Physical  examination, vital  parameter  assessment and wellbeing assessment
were performed to all study subjects during each period & during check-out, to ensure
safety of the study.
       The laboratory post study values were compared with pre-study laboratory
test  values.  If  any  clinically  significant  deviations  were  seen,  the  subjects  were
followed up and appropriate medical care was provided.
REPORTING OF AE AND SAE
       In case of Serious Adverse Events (SAE), the event should be reported to
the sponsor immediately by telephone and then the copy of SAE form to be faxed or
scanned & sent by email in 24 hrs & the same shall be sent through post. In turn the
sponsor  should  report  to  the  regulatory  authority  with  in  10  calendar  days.  The
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investigator  should  inform the  ethics  committee  about  SAE in  within  24hours  in
writing.  
       In case of AEs, the investigator needs to complete the AE form and may
send the copies to the sponsor and IEC in his/her own discretion.  
FOLLOW UP OF AE AND SAE
        After  the  initial  AE /  SAE report,  the  investigator  is  required  to
proactively follow each subject and provide further information to the sponsor on the
subject’s condition.
       All AEs and SAEs will be followed until resolution, until the condition
stabilizes, until the event is otherwise explained or until the subject is lost from follow
up.  The  investigator  will  ensure  that  follow  up  includes  any  supplemental
investigations as may be indicated to elucidate the nature and / or causality of the AE
or  SAE.  This  may  include  additional  laboratory  tests  or  investigations,  histo
pathological examinations or consultation with other health care professionals.
DOCUMENTATION OF DATA:
PROTOCOL DEVIATIONS AND AMENDMENTS
 All important deviations related to study inclusion or exclusion criteria, conduct of
the study, subject management were informed to the sponsor and were mentioned in
the final report.
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BIOANALYTICAL METHODOLOGY
                 
                       A validated Liquid Chromatography and Mass Spectroscopy   (LC-
MS/MS) method was employed for the estimation of Trimebutine in plasma. Samples
with drug concentration greater than upper limit of the validated range of the analysis
were  diluted  using  the  appropriate  drug  free  biological  fluid  and  reanalyzed  by
dilution integrity testing.
Incurred sample analysis was carried out for a minimum 10% of total study samples.
Samples, which were below the lower limit of quantification (LLOQ) was reported as
below limit of quantification (BLQ).
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INSTRUMENT
Mass Spectrometric Conditions
Agilent Infinity 1290-Binary Pump, Auto Sampler, Degasser, Agilent  
6460 Triple  Quad LC/MS.
S.No                  Parameter
1 Ion Source ESI+Agilent Jet Stream
2 Polarity Positive
3 Gas Temp (°C) 300
4 Gas Flow ( l/min) 8
5 Nebulizer (psi)                            30
6 Sheath Gas Temp (°C) 350
7 Sheath Gas Flow ( 1/min ) 7
8 Capillary (V) 4000
9 Nozzle Voltage (V) 500
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Multiple Reacting Mode Conditions
S.No. Parameter Trimebutine Verapamil (IS)
1 Precursor Ion 388.2 455.3
2 Product Ion 343.2 165.1
3 Fragmentor (V) 98 157
4 Collision Energy (V) 5 26
Chromatographic Conditions:
S.N
o.
Parameters
1 Column GeminiC18,50x2.00mm,3µ
2 Mobile Phase Acetonitrile:2mM Ammonium acetate (90:10)
3 Flow Rate 0.2 mL/minute
4 Auto sampler Temperature 6°C
5 Column Oven Temperature 30°C
6 Injection Volume 5 µL
7 Run Time 2.5minutes
8 Retention time
1.4 ±0.5minutes for Analyte and 1.2 ±0.5minutes
for IS
VALIDATION  METHOD  OF TRIMEBUTINE:
      Bioanalytical procedure:
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             Materials Required:
  Trimebutine (Working Standard)
 verapamil (Internal Standard)
 Methanol (HPLC Grade)
 Di Sodium Hydrogen Ortho Phosphate (General Reagent)
 . Tert Butyl Methyl Ether
 . Acetonitrile  (HPLC Grade)
 . Milli Q Water
 Formic acid (General Reagent)
 Ammonium Acetate   (HPLC Grad
Preparation of Reagents and Solutions
Preparation of Diluent : (Methanol: Water(50:50)v/v)
Transfer 250mL of Methanol in 500 mL reagent bottle containing 250mL of MilliQ 
Water and mix well. Fill the respective ‘SOP Forms’ and label the solution as per 
relevant SOP.
Preparation of Buffer I :( 2mM Ammonium acetate)
Weigh accurately about 0.1542 gm of Ammonium acetate and transfer into a 1000mL 
Reagent bottle.  Dissolve it in Water and make up the volume with the same to 
produce a 1000mL solution. Mix well and sonicate it for 5 minutes and filter through 
0.22µ membrane filter. Fill the respective ‘SOP Forms’ and label the solution as per 
relevant SOP.
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Preparation of Mobile Phase:
 Preparation of Acetonitrile: Buffer I(90:10) v/v)
Transfer 900mL of Acetonitrile into a clean 1000mL reagent bottle containing 100 
mL of 2 mM Ammonium acetate. Mix well and sonicate for 5 minutes. Fill the 
respective ‘SOP Forms’ and label the solution as per relevant SOP.
Preparation of 0.1M Di Sodium Hydrogen Ortho Phosphate :
Weigh accurately about 1.4196gm of Di Sodium Hydrogen   Ortho Phosphate and
Transfer to 100 mL Standard flask. Make up the volume to 100 mL with Milli Q
water, mix well and sonicate it for 5 minutes and filter through 0.22µ membrane
filter. Fill the respective ‘SOP Forms’ and label the solution as per relevant SOP.
Preparation of Rinsing solution: (Methanol: Water (90:10) v/v)
Transfer 900mL of Methanol in 1000mL reagent bottle containing 200mL of Milli Q-
Water. Mix well the reagent bottle.  Fill  the respective ‘SOP Forms’ and label the
solution as per relevant SOP.
Preparation of Trimebutine  Stock Solution:
Weigh  accurately  about  2mg  of  Trimebutine maleate  and  transfer  into  a  2mL
volumetric flask. Dissolve it in Methanol and make up the volume with the same to
produce a solution of 1mg/mL. Fill the respective ‘SOP Forms’ and label the solution
as per relevant SOP.
Preparation of CC Samples Stock Dilutions:
From  Trimebutine stock solutions ,Stock Dilutions ranging from 262.4549ng/mL to
30031.3643ng/mL with (Methanol: Water / 50:50), as provided in the Table No.1
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Table No. 1 - Stock Dilution for Calibration Standards
S.NO Initial Stock 
Conc.   
(ng/mL)
Volume of 
Stock taken   
(mL)
Volume of 
Diluent 
added (mL)
Total Volume 
of Final 
Solution  (mL)
Final Stock 
Conc.           
(ng/mL)
SS1 79029.9060 3.800 6.200 10 30031.3643
SS2 30031.3643 8.000 2.000 10 24025.0914
SS3 24025.0914 6.300 3.700 10 15135.8076
SS4 15135.8076 6.000 4.000 10 9081.4846
SS5 9081.4846 3.400 6.600 10 3087.7048
SS6 3087.7048 5.000 5.000 10 1543.8524
SS7 1543.8524 3.400 6.600 10 524.9098
SS8 524.9098 5.000 5.000 10 262.4549
Preparation of Calibration Standards and Quality Control Samples 
 Trimebutine Calibration Standards in Human Plasma:
From  Trimebutine CC  Stock  Dilutions,  Calibration  Standards  in  Human
K3ETDA plasma ranging from  5.2491ng/mL – 600.6273ng/mL for  Trimebutine as
provided in the Table No.2 
Table No. 2 – Trimebutine Calibration Standards in Human plasma
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S.NO
Stock Concns of  
Trimebutine  
(ng/mL)
Volume of 
Stock taken 
(mL)
Volume of 
Plasma 
added (mL)
Total Volume 
of Final 
Solution(mL)
Final Trime- 
butine Conc. 
In human 
plasma           
(ng/mL)
SS1 30031.3643 0.200 9.800 10.000 600.6273
SS2 24025.0914 0.200 9.800 10.000 480.5018
SS3 15135.8076 0.200 9.800 10.000 302.7162
SS4 9081.4846 0.200 9.800 10.000 181.6297
SS5 3087.7048 0.200 9.800 10.000 61.7541
SS6 1543.8524 0.200 9.800 10.000 30.8770
SS7 524.9098 0.200 9.800 10.000 10.4982
SS8 262.4549 0.200 9.800 10.000 5.2491
 Stock concentrations may vary depending upon the amount of compound weighed
and the purity of the compound.
Preparation of Verapamil (IS) Stock Solution:
Weigh accurately about 2mg of Verapamil hcl and transfer into a 2mL volumetric
flask. Dissolve it in Methanol and make up the volume with the same to produce a
solution of 1mg /mL strength of Verapamil.
Preparation of Verapamil (IS) Standard Stock Solution Dilutions:
                From Verapamil hcl Stock Solution, working Concentration of the Internal
Standard Solution (about 100ng/mL) were prepared   as described in the Table No.3
(below) 
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TABLE 3 -   Preparation of Internal Standard Stock Solution
   Initial  Stock
 Conc. 
(µg/mL)
Volume 
taken (µl)      
Volume of 
Diluent 
(mL)        
   Final
Volume(mL)
Final Stock Conc.
(µg/mL)
1000000.0000 0.020 1.980 2.000 10000.000
10000.000 1.000 99.000 100.000 100.000
QUALITY CONTROL  (QC) SAMPLES:    
Preparation of Trimebutine QC Samples Dilutions:
                  From  Trimebutine Stock  Solution,  Stock  Dilutions  ranging
266.4016ng/mL to 23708.9718ng/mL with (Methanol: Water / 50:50), as provided in
the Table No.4
Table No. 4 - Stock Dilution Trimebutine Quality Control Samples.
Initial Stock 
Conc.   
(ng/mL)
Volume 
of Stock 
taken       
(mL)
Volume of 
Diluent added
(mL)
Total Volume 
of Final 
Solution
(mL)
Final Stock 
Conc.           
(ng/mL)
79029.9060 3.000 7.000 10 23708.9718
23708.9718 5.100 4.900 10 12091.5756
12091.5756 2.400 7.600 10 2901.9781
2901.9781 2.700 7.300 10 783.5341
783.5341 3.400 6.600 10 266.4016
Preparation of  Trimebutine Quality Control Samples in Human Plasma:
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                       From Trimebutine QC Stock Dilutions ,  Quality Control samples in
Human K3ETDA plasma ranging 5.3280ng/mL -474.1794ng/mL for  Trimebutine as
provided in the Table No.5
Table  5- Trimebutine Quality Control Samples In Human Plasma
Initial Stock 
Conc.   (ng/mL)
Volume of Stock 
taken                
(mL)
Volume of 
Plasma 
added(mL)
Total Volume of
Final 
Solution(mL)
Final 
Stock 
Conc.    
(ng/mL)
23708.9718
0.200 9.800 10.000
474.179
4
12091.5756
0.200 9.800 10.000 241.831
5
2901.9781 0.200 9.800 10.000 58.0396
783.5341 0.200 9.800 10.000 15.6707
266.4016 0.200 9.800 10.000 5.3280
Sample Preparation:  
 
Extraction Type – Solid Phase Extraction
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 Withdraw  the  CC/QC  samples  from  intended  storage  area  and  keep  for
thawing at room temperature.
 Aliquot 100µL of sample to labeled RIA vials.  
 Add 50µL of internal  standard (Verapamil,  100ng/mL) into all the samples
except blank and vortex.
 Add 100 µL of 0.1M Disodium hydrogen ortho phosphate to all the samples
and vortex.
 Add 3 mL of Tert Butyl Methyl Ether into all the samples and cap them.
  The samples were kept in vibramax for 10 minutes at 2000 rpm.
 Then The samples were Centrifuged at 4000 rpm at 4 ºC for 10 min.
 250 µL of organic layer was transfered into respective labeled RIA vials.
 Kept the samples in Nitrogen evaporator at 40º C and 15 psi until dryness.
 The sample were Reconstitute with 0. 1mL of Mobile phase and vortex.
 The sample was Transfer  into inserts in appropriately labeled auto sampler
vials and load the samples into LC-MS/MS
Trimebutine – Analytical Data Processing
The  unknown  concentration  of  blood  sample  is  calculated  from  the  following
equation by utilizing linear regression with 1/x² as weighting factor.
Y= mX+b
Where,                                 Y = Peak area ratio of Trimebutine
                                             X = Concentration of Trimebutine
                                             m = Slope of the Calibration Curve Trimebutine
                                        b = Intercept of the Calibration Curve Trimebutine.
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                                PHARMACOKINETIC ANALYSIS
Pharmacokinetic  analysis  was  done  by  Non-  compartmental  method  of
analysis using the WinNonlin® Version 5.3.
          The following pharmacokinetic parameters were calculated−
Primary pharmacokinetic parameters:  
    Cmax :
 Maximum measured plasma concentration over the time span specified.
  AUC0-t
 
:
              The area under the plasma concentration versus time curve, from time zero to
the last time point with measurable concentration, calculated by the linear trapezoidal
method.
  AUC₀-∞:
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              The area under the plasma concentration versus time curve, from time zero to
time  infinity.  AUC0-∞ is calculated as the sum of the AUC0-t plus the ratio of the last
measurable concentration to the elimination rate constant. 
Secondary Pharmacokinetic parameters:
 Tmax:                       
                Time of maximum  measured  plasma concentration.  If the maximum value
occurs at more than one point, Tmax is defined as the first point with this value in each
period.  
 
Kel: 
              Apparent first order elimination or terminal rate constant calculated from a
semi-log plot of the plasma concentration versus time curve.
  T1/2: 
              Time required for the plasma drug concentration to decrease by one half of
the drug. 
               If pre-dose concentration was found to be less than or equal to 5% of mean
Cmax, the value was considered as such for calculation. If the pre-dose concentration of
a  subject  is  more  than  5% of  Cmax,  the  respective  subject  will  be  dropped  from
bioequivalence analysis.
While Pharmacokinetic data is reported,  the number of points of the terminal log-
linear phase used to estimate the terminal rate constant (Kel) will be reported. 
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AUC0-t shall cover at least 80% of AUC0-∞. Subjects will not be excluded from the
statistical analysis if AUC0-t covers less than 80% of AUC0-∞. 
STATISTICAL ANALYSIS
                         The descriptive statistics such as mean, standard deviation, geometric
mean  and  coefficient  of  variation  were  reported  for  the  relevant  pharmacokinetic
parameters, Cmax, AUC0-t and AUC0-∞ and secondary parameters, Tmax, t1/2 nad Kel were
estimated for both Test and Reference products.
Analysis of variance (ANOVA):
                           ANOVA was performed using the SAS® statistical software
(version:  9.2)  General  linear  model  (GLM)  procedure.  The  Ln-transformed
pharmacokinetic  parameters  (Cmax,  AUC0-t and  AUC0-∞)  were  analyzed  using  an
ANOVA model  with the main effects  of  treatment,  period  and sequence  as  fixed
effects and subjects nested within sequence as random 
           A separate ANOVA model was used to analyze each of the parameters. The
sequence effect was tested at the 0.10 level of significance using the subjects nested
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within the sequence mean square from the ANOVA as the error term. As other main
effects were tested at the 0.05 level of significance against the residual error (mean
square error) from the ANOVA as the residual error. 
             Sum of squares (Type III) was reported and probability values (P) were
derived from it. For all analyses, effects were considered statistically significant, if the
probability associated with “F” was less than 0.05. 
90 % Confidence Intervals (CI):
              Consistent with the two one-sided tests for bioequivalence, 90% confidence
intervals for the difference between the test and reference means was calculated for
the untransformed data and log transformed data.
  The confidence limits were expressed as percentages of the least square mean (LSM)
of the reference product. Using the confidence limits of the above CI and the LSM of
the reference product, an approximate 90% CI for the ratio of the test and reference
product means was calculated.
Intra-subject variability:
The intra-subject variability for each of the pharmacokinetic parameters reflect
the  residual  variability  after  accounting  for  the  difference  between  the  subjects,
periods,  and  treatments  and  was  reported  in  terms  of  the  overall  co-efficient  of
variation (CV%), and separately, from the ANOVA results using both untransformed
and log-transformed data using the formula,
Untransformed data = 100* (EMSE-1)1/2
Where, MSE is mean square error.
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Bioequivalence criteria:         
Based on the statistical results of 90% confidence intervals of the ratios of the
means (Test/Reference) for Ln-transformed pharmacokinetic parameters Cmax, AUC0-t
and AUC0-∞, conclusion was drawn to find whether the test product is bioequivalent to
the reference product or not. 
Bioequivalence was concluded,  if  the Test  to Reference (T/R) ratios and the 90%
confidence interval for the ratios for the means fall within the acceptance range of
80% -125% for the pharmacokinetic parameters, Cmax, AUC0-t  and AUC0-∞.
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RESULTS
This single oral dose comparative BA/BE study was undertaken to evaluate
the  bioequivalence  and  also,  to  monitor  the  adverse  events  of  test  product
Trimebutine 200 mg capsules in healthy subjects.
The study was designed to evaluate and compare the relative bioavailability of
test and reference products of Trimebutine
In this two period two way cross over study, 48 subjects who met the study
inclusion and exclusion criteria were enrolled.
There was a washout period of 5 days between the two periods. The overall
duration of the study was 09 days including the wash out period. Blood samples were
collected at the predetermined time points to elicit the pharmacokinetic profiles of
Trimebutine.
In  this  study,  Test  and  Reference  product  containing  Trimebutine were
evaluated for the safety upon single dose administration to normal healthy adult male
and non- pregnant female subjects under fasting conditions. 
Vital parameters measured at the scheduled time intervals were normal and
within the acceptable range for all study subjects.
There was no death or serious adverse event reported in this study.
The Plasma concentration level of Trimebutine was determined by a validated
LC-MS/MS method.
Pharmacokinetic analysis of test and reference products were evaluated based
on measured plasma concentration of the drugs using Non compartmental Model of
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WinNonlin® v  5.3.  Primary  pharmacokinetic  parameters  like  Cmax,  AUC0-t, and
secondary pharmacokinetic  parameters  like AUC0-∞,  Tmax,VD,CL,  Kel,  and T1/2 were
calculated.
The  statistical  analysis  was  performed  using  the  SAS®  statistical  software
(version:9.2)
Pharmacokinetic Parameters
The  pharmacokinetic  parameters  were  estimated  by  using  WinNonlin  Software
version 5
TABLE-6: Mean values of various pharmacokinetic parameters for Trimebutine
Parameters (Units) Trimebutine  (Mean ± SD )
Test Reference
Cmax (ng/ml) 107.674± 121.571 107.162± 61.015
AUC0- t (ng.h/ml) 139.194± 149.903 135.307± 79.670
AUC0-∞ (ng.h/ml)
155.939± 164.702
.150.772± 83.149
tmax (hr) 0.998± 0.423 0.991 ± 0.497
VD (ml)
3506236.721±
2887193.223
3584623.509±2647885.163
CL (ml/hr) 2196302.925±1805242.163 1824528.769±1196714.197
Kel  (hr-1)  0.711±0.512 0.564 ± 0.232
T1/2 (hr) 1.635 ±1.625  1.625±1.396 
AUC0-t /AUC0-∞ X 100  12.319±9.400  12.717± 9.609
Trimebutine:
 Cmax-- Peak or maximal Plasma concentration:
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                Mean values (±SD) of Cmax for Trimebutine , treatment Test was 107.674±
121.571 ng/ml & for Reference was 107.162± 61.015 ng/ml. 
The Test / Reference (T/R) ratio of least square mean of log transformed Cmax was
104.96 %
with 90% confidence interval LCL=100.79 %  and UCL= 109.29 %.
 AUC0-t --Area under the concentration-time curve 
                Mean values (±SD) of Cmax for Trimebutine , treatment Test was 139.194±
149.903 ng/ml & for Reference was 135.307± 79.670 ng/ml 
The Test / Reference  (T/R) ratio of least square mean of log transformed AUC0-t was
108.77 % with 90% confidence interval LCL= 106.25 % and UCL= 111.34 %.
 AUC0-∞-- Area under the Concentration-Time curve 
               Mean values (±SD) of AUC0-∞ for Trimebutine, treatment T was 2077.516±
707.812 ng.h/ml & for Reference was 1907.487± 597.092 ng.h/ml.
The Test / Reference  (T/R) ratio of least square mean of log transformed AUC0-t was
108.18 % with 90% confidence interval LCL= 105.63 % and UCL= 110.80 %.
 Tmax:
                Mean values (±SD) of Tmax for Trimebutine, treatment T was 0.998± 0.423
hr & for Reference was 0.991 ± 0.497 hr.
 VD(ml):
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                   Mean values  (±SD) of VD for  Trimebutine, treatment  T were
3506236.721±2887193.223  &  for  treatment  R  were  3584623.509±2647885.163
ng.h/ml .
 CL(ml/hr):
                   Mean values  (±SD) of  CL for  Trimebutine, treatment  T were
2196302.925±1805242.163&  for  treatment  R  were  1824528.769±1196714.197
ng.h/ml.
 Kel(hr-1):
                  Mean values (±SD) of Kel for Trimebutine, treatment T were 0.711±0.512
& for   treatment R were 0.564 ± 0.232.
 T1/2(hr):
                   Mean values (±SD) of T1/2 for Trimebutine, treatment T were 1.635
±1.625 & for treatment R were 1.625±1.396.
 AUC0-t /AUC0-∞ X 100 % :
                   Mean values (±SD) of AUC0-t /AUC0-∞ X 100 for Trimebutine,
Treatment T were 12.319±9.400 & for treatment R were 12.717± 9.609 .
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TABLE 7- LATIN SQUARE DESIGN:  ANOVA TABLE
Maximum Plasma Concentration (Cmax):
Source DF Type III SS Mean Square F Value Pr > F
FORMULATION 1 0.14659822 0.14659822 0.90 0.3479
SEQUENCE 1 0.02781272 0.02781272 0.04 0.8455
PERIOD 1 0.14013784 0.14013784 0.86 0.3587
SUBJECT(SEQUENCE) 45 32.59297900 0.72428842 4.45 <.0001
Table-7  shows  the  Latin  square  design  using  ANOVA  for  Cmax.  The  Subject
(Sequence) effect  show  statistically  significant  difference  between  the  test  and
reference products. The sequence effect, period effect and formulation effect does not
show any statistically significant difference between the test and reference products.
Formulation effects was  non-significant  (at  5  %  level  of  significance),  when
ANOVA was applied on Ln-transformed data for Cmax of Trimebutine. 
Sequence effects was non-significant (at 10 % level of significance), when ANOVA
was applied on Ln-transformed data for Cmax of Trimebutine. 
Period effects was non-significant (at 5 % level of significance), when ANOVA was
applied on Ln-transformed data for Cmax of Trimebutine. 
Subject  (Sequence) effects was  significant  (at  5  %  level  of  significance),  when
ANOVA  was  applied  on  Ln-transformed  data  for  Cmax  of  Trimebutine.  Such
significant effects do not have impact on the study results.
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TABLE 8
Cmax
Mean SD Min Max
Test
Reference
Table 8 shows maximum, minimum, mean and SD values of  Cmax for both Test and
Reference products. 
Figure 7 shows the graphical representation of table 8
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TABLE 9- LATIN SQUARE DESIGN:  ANOVA TABLE
Area under the curve (AUC0-t):
Source DF Type III SS Mean Square F Value Pr > F
FORMULATION 1 0.18986900 0.18986900 1.58 0.2158
SEQUENCE 1 0.03913736 0.03913736 0.04 0.8361
PERIOD 1 0.96165336 0.96165336 7.98 0.0070
SUBJECT(SEQUENCE) 45 40.66622420 0.90369387 7.50 <.0001
Table-9 shows the Latin square design using ANOVA for AUC0-t.  The period effect
and Subject (Sequence) effect show statistically significant difference between the test
and reference products. Formulation effect and Sequence effect  does not show any
statistically significant difference between the test and reference products.
Formulation effects was  non-significant  (at  5  %  level  of  significance),  when
ANOVA was applied on Ln-transformed data for AUC0-t of Trimebutine. 
Sequence effects was non-significant (at 10 % level of significance), when ANOVA
was applied on Ln-transformed data for AUC0-t of Trimebutine. 
Period effects was  significant  (at  5  % level  of  significance),  when ANOVA was
applied on Ln-transformed data for AUC0-t of Trimebutine. Such significant effects do
not have impact on the study results.
Subject  (Sequence) effects was  significant  (at  5  %  level  of  significance),  when
ANOVA  was  applied  on  Ln-transformed  data  for  AUC0-t  of  Trimebutine.  Such
significant effects do not have impact on the study results.
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TABLE 10
AUC0-t
Mean SD Min Max
Test
Reference
Table 10 shows maximum, minimum, mean and SD values of AUC0-t  for both Test
and Reference products. 
Figure 8 shows the graphical representation of table 10
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TABLE 11
AUC0-∞
Mean SD Min Max
Test
Reference
Table 11  shows maximum, minimum, mean and SD values of AUC0-∞  for both Test
and Reference products. 
Figure 9  shows the graphical representation of table 11
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TABLE 12
TIME OF MAXIMUM MEASURED PLASMA CONCENTRATION
Tmax
Mean SD Min Max
Test
Reference
Table 12 shows maximum, minimum, mean and SD values of Tmax for both Test and
Reference products. 
Figure 10 shows the graphical representation of table 12
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TABLE 13
Volume of Distribution (VD)
Mean SD Min Max
Test
Reference
Table 13 shows maximum, minimum, mean and SD values of VD
 
for both Test and
Reference products. 
Figure 11 shows the graphical representation of table 13
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TABLE 14
Clearance (CL)
Mean SD Min Max
Test 2196302.925 1805242.163 183390.68 8623189.61
Reference 1824528.769 1196714.197 489692.34 6169700.36
Table 14 shows maximum, minimum, mean and SD values of CL
 
for both Test and
Reference products. 
Figure 12 is the graphical representation of table 14
.
TABLE 15 
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Kel
Mean SD Min Max
Test
Reference
Table 15 shows maximum, minimum, mean and SD values of Kel
 
for both Test and
Reference products. 
Figure 13 shows the graphical representation of table 15
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TABLE 16
Thalf
Mean SD Min Max
Test
Reference
Table 16 shows maximum, minimum, mean and SD values of Thalf for both Test and
Reference products. 
Figure 14 shows the graphical representation of table 16
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Figure  15:  LINEAR  PLOT  OF  MEAN  PLASMA  TRIMEBUTINE
CONCENTRATION VS TIMEPOINTS
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Linear plot of mean plasma Trimebutine concentration vs timepoints
The above Figure-15 shows the Means Plasma Concentration Vs various time
points of both the Test and Reference products (Trimebutine).
Dept.of Pharmacology                                             JKKMMRF College of Pharmacy98
Chapter 5                                                                                                        Results 
Figure  16:  SEMILOG  PLOT  OF  MEAN  PLASMA  TRIMEBUTINE
CONCENTRATION VS TIME POINTS
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Semilog plot of mean plasma Trimebutine concentration vs timepoints
The above Figure-16 shows the Semilog plot of Mean Plasma Concentration Vs
various time points of both the Test and Reference products (Trimebutine).
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MEAN PLASMA CONCENTRATION:
Time (hours) TEST REFERENCE
0.00 0.0000 0.0000
0.17 0.0000 0.0000
0.33 7.3773 10.9368
0.50 37.8521 40.4967
0.67 71.7015 66.4532
0.83 79.6067 75.9546
1.00 76.1783 71.5594
1.25 59.1450 57.4993
1.50 49.7126 48.0618
1.75 41.9555 40.8818
2.00 34.1117 33.7060
2.33 25.9538 26.8831
2.67 19.5778 21.0533
3.00 16.3626 16.3978
4.00 8.8304 9.0843
6.00 1.9514 2.6540
8.00 0.9628 0.7977
12.00 0.3765 0.2172
18.00 0.2279 0.0000
24.00 0.1132 0.0000
36.00 0.0000 0.0000
48.00 0.0000 0.0000
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DISCUSSION
                            Bioequivalance studies are fundamentally satisfied through single
dose administration. The focus is on the rate and extent of absorption of the active
ingredient.  They  are  conducted  in  healthy  normal  subjects  under  fasting  or  fed
conditions.  Most  comparative  bioavailability  studies  are  conducted  to  identify  the
quantitative with intravenous dose,  modified release with conventional  preparation
and for a generic product, test and reference.
Nowadays,  bioequivalence studies are a pivotal part of registration dossiers.
These studies measure the bioavailability of two more formulations of the same active
ingredient. The purpose of the study is to show the bioavailability of the formulations
under investigation is equal. Based on the conclusion that the therapeutic qualities of
these formulations are identical, these formulations can be interchangeable.
In  this  study,  Test  and  Reference  product  containing  Trimebutine 200  mg
capsules  were  evaluated  for  the  safety upon single  dose  administration  to  normal
healthy adult male and non pregnant females’ subjects under fasting conditions.
There was a washout period of 5 days between the two periods. The overall
duration of the study was 09 days including the wash out period.  Blood samples were
collected at the predetermined time points to elicit the pharmacokinetic profiles of
Trimebutine
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Vital parameters measured at the scheduled time intervals were normal and
within the acceptable range of all study subjects.
This  study  was  conducted  with  Trimebutine 200  mg  (test)  and  Digedrat  200  mg
(reference) to establish the drugs concentration versus time profile and the results of
the pharmacokinetic analysis of  Trimebutine of the test (T) product were compared
with the reference(R) product. 
Analysis of variance for Ln-transformed pharmacokinetic parameters revealed
that  there  was  no significant  variation between  test  and  reference  formulation  for
these three primary pharmacokinetic parameters Cmax and AUC0-t, & AUC0-∞.
Cmax: 
The statistical analysis  did not show any significant difference between the
groups.  The  geometric  mean  ratio  was  within  the  limits  of  reference  confidence
interval which was found to be 100.79 % to109.29 %. (80 to 125%). This confirms
the bioequivalence of the products.
AUC 0-t: 
The statistical analysis  did not show any significant difference between the
groups.  The  geometric  mean  ratio  was  within  the  limits  of  reference  confidence
interval  that  was  found  to  be  106.25  %  to  111.34  %  (80  to  125%).  Therefore,
bioequivalence can be concluded. 
AUC 0-∞:  
The statistical analysis  did not show any significant difference between the
groups.  The  geometric  mean  ratio  was  within  the  limits  of  reference  confidence
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interval which was found to be 105.63 % to110.80 % (80 to 125%), which confirms
bioequivalence.
90% Confidence Interval:
            The 90% confidence intervals of the T/R ratio of Ln- transformed Cmax  and
AUC0-t, AUC0-∞ were within the bioequivalence range of 80%-125%. 
 Post study assessment of the hematological and biochemical parameters showed no
significant changes on comparing with the respective baseline parameters.
The above parameters are similar which suggested that Trimebutine (Test) and
Digedrat (Reference) were bioequivalent.
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SUMMARY AND CONCLUSION
   
       The study,  Trimebutine 200 mg (test) and Digedrat 200 mg (reference)
capsules  were  evaluated  for  the  safety upon single  dose  administration  to  normal
healthy adult male and non pregnant females subjects under fasting conditions.
         There was a washout period of 5 days between the two periods. The
overall duration of the study was 09 days including the wash out period.
                     This study was conducted to establish the drugs concentration versus
time profile and the results  of the pharmacokinetic analysis  of  Trimebutine of the
test(T) product were compared with the  reference(R) product. 
                      The Means Plasma Concentration Vs various time points of both the
Test and Reference products (Trimebutine), were similar,at all the scheduled  time
points.
                      Analysis of variance for Ln-transformed pharmacokinetic parameters
revealed that there was no significant variation between test and reference formulation
for these three primary pharmacokinetic parameters Cmax and AUC0-t, & AUC0-∞. 
                      The 90% confidence intervals of the T/R ratio of Ln- transformed Cmax,
and AUC0-t , AUC0-∞ were within the bioequivalence range of 80%-125%. 
 
                         In conclusion, in the present study, Trimebutine 200 mg capsule is
bioequivalent to Digedrat (Trimebutine) 200 mg tablet in 48 healthy subjects under
fasting conditions. Trimebutine 200 mg capsule was well tolerated.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy104
Chapter 8                                                                                                  Bibliography
BIBLIOGRAPHY
1.  Guidance  for  industry.  Bioavailability  and  bioequivalence  studies  for  orally
administerd drug products.  General  considerations.  U.S Department  of  Health  and
Human services.  Food and Drug Administrations.  center  for  Drug Evaluation and
Research(CDER),october 2000.
2.U.S.  department  of  health  and  human  services,  food  and  drug  
administration, center  for drug evaluation and research (CDER), BP. Guidance for
Industry,  Bioavailability and Bioequivalence Studies for Orally Administered Drug
Products - General Considerations, March 2003.
3.Laurence L Brunton, John S Lazo and Keith L Parker. Goodman and Gilman. The
Pharmacological Basis of Therapeutics. 10th edition. P.1768-1769, 21-30.
4.H. L. Sharma and K. K. Sharma. Desai C. Principles of Pharmacology. Indian
Journal  of  Pharmacology  2011.  Second  Edition,  New  Delhi:  Paras  Medical
Publishers; 2007, p 27-31.
5. David E. Golan. Principles of Pharmacology: The Pathophysiologic basis of drug
therapy. 2nd edition p. 32 – 34.
6. The European agency for the evaluation of medicinal products--Committee for
proprietary  medicinal  products  for  human use(CPMP),  Draft  Guideline  on  the
Investigation of Bioequivalence (Jan 2010)  p.3 – 6.
7.Albert  K.S  (1980)  Drug  Absorption  and  Disposition:  Statistical  Considerations
Amer. Pharm. Assoc.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy105
Chapter 8                                                                                                  Bibliography
8.  Gibaldi  M, Perrier  D.  Biopharmaceutics  and Clinical  Pharmacokinetics,  Lea  &
Febiger, Philadelphia, Fourth Edition; 1991  p: 24-79
9. Barar FSK. Essential of Pharmacotherapeutics, S. Chand & Company publishers,
Tenth Edition; 2005; p. 164 –169.
10.Brahmankar DM, Jaiswal SB. Biopharmaceutics and Pharmacokinetics A Treatise:
Ed: Jain MK, Vallabh prakashan, First Edition; 1995; p: 282 – 305.
11. Venkateswarlu  V.  Biopharmaceutics  and  Pharmacokinetics,  Pharma  Book
Syndicate; 2006; p: 340-349.
12.U.S.Department  of  Health  and  Human  Services.  Food  and  Drug  
Administration  Center  for  Drug  Evaluation  and  Research  (CDER).  
December 2002, p.8 – 10.
13.  Martin  dale:  The  Complete  Drug  Reference.  Ed.  By Sean  C Sweetman.  35th
Edn.Pharmacetical press,USA.p.420.
14. Central Drugs Standard Control Organization. Guidelines for Bioavailability
and Bioequivalence Studies. New Delhi: 2005, p.1 – 34.
15. Shein-Chung, Liu JP. Design and Analysis Of Bioavailability and  Bioequivalence
Studies.Marcel  Dekker  Inc,  New  York,  2nd Edition,  2000,  
P. 1-3.
16. . Madan PL. Bioavailability and Bioequivalence, the Underlying Concepts,  US
Pharm, 1992; 17: H10-H30
17. Hohnloser, S.H. Proarrhythmia with class III anti-arrhythimc drugs: types, risk, 
and management. Am. J. Cardiol., 1997, 80, 82G-89G.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy106
Chapter 8                                                                                                  Bibliography
18. Viskin, S.; Justo, D.; Zeltser, D. Drug induced prolongation of QT interval. N. 
Engl. J. Med., 2004, 350, 1013-1022.
19. Ducroq,     J.;  Rouet,   R.;  Puddu,    P.E.;  Sallé,  L.;  Tabourel,   C.; Ducouret, P.;
Gérard, J.L. Electrophysiological effects of azimilide in   an in   vitro  model   of  
simulated-ischemia     and   reperfusion   in guinea-pig ventricular myocardium. Eur. 
J. Pharmacol., 2005, 518, 165-174.
20. Kountouras J, Chatzopoulos D, Zavos C, Boura P, Venizelos J, Kalis A. Efficacy 
of trimebutine therapy in patients with gastroesophageal reflux disease and irritable 
bowel syndrome. Hepatogastroenterology. 2002; 49: 193-197. 
21. Kountouras J, Zavos C, Chatzopoulos D. H pylori infection and reflux 
oesophagitis. Gut. 2004; 53: 912. 
22. Kaji M, Fujiwara Y, Shiba M, Kohata Y, Yamagami H, Tanigawa T, et al. 
Prevalence of overlaps between GERD,  FD and IBS and impact on health-related 
quality of life. J Gastroenterol Hepatol. 2010; 25: 1151-1156. 
 23. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-
immunological model with relevance for other IBS and functional dyspepsia. J 
Neurogastroenterol Motil.2010;16:30-34
24. Kruszewska H, Zareba T, Tyski S. Examination of antimicrobial activity of 
selected non-antibiotic drugs. Acta Pol Pharma. 2004; 61: 18-21.
24.MacDonald AJ, Peden NR, Hayton  R, Mallinson CN, Roberts D, Wormsley KG. 
Symptom relief and the placebo effect  in  the  trial  of  an  anti-peptic  drug. Gut 
1980;  22: 323–6.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy107
Chapter 8                                                                                                  Bibliography
25.de Craen AJ, Moerman DE, Heisterkamp SH, Tytgat GN, Tijssen  JG,  Kleijnen  J.
Placebo  effect  in  the  treatment  of  duodenal ulcer. Br J Clin Pharmacol  1999; 48: 
853–60.  
26.PubMed J Int Med Res. 1997 Sep-Oct;25(5):225-46.
27.Modulon® (trimebutine  maleate) Tablets-Product  Monograph  Aptalis  Pharma
Canada Inc.
28. Arsac M. Expérimentation clinique du débridat en chirurgie générale.  Hip. 
Inf.Therap. 1972;3,2:103-106. 
29.  Bantman, C. Conclusions d’une application du débridat en médecine pratiquedans
les colopathies.  Hop. Inf. Therap. 1972; 3, 4:213-214. 
30. Cinqualbre J, Lampert M, Avalos S, Forster E. Essai clinique d’un nouveau 
péristaltogène agissant au niveau des synapses digestives. J. Med. Strasbourg1973; 4, 
12:973-976. 
31.  Cope A. Étude clinique comparative de l’association clidinium (br)- 
chlordiazepoxide et de la trimébutine dans le traitment des colopathies fonctionnelles. 
Med.  Chir. Dig. 1981; 10, 8:713-717. 
32. Corazza G R, Vaira D, Milletti S, Vanzini S, Gasbarrini G.  Controlled clinical 
evaluation of pinaverium bromide and trimebutine in functional disorders of colon.  
Acta Therapeutica 1983; 9:383-389.
33."irritable bowel syndrome" at Dorland's Medical Dictionary
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy108
Chapter 8                                                                                                  Bibliography
34. Malagelada,  JR  (2006).  "A  symptom-based  approach  to  making  a  positive
diagnosis  of  irritable  bowel  syndrome with  constipation". International  journal  of
clinical practice60 (1): 57–63. 
35. Cash, BD; Schoenfeld, P; Chey,  WD (2002). "The utility of diagnostic tests in
irritable bowel syndrome patients:  A systematic  review". The American journal of
gastroenterology 97 (11): 2812–9.
36.Spiller  R,  Garsed  K  (May  2009).  "Postinfectious  irritable  bowel
syndrome". Gastroenterology 136 (6):1979–88.
37. Chang L (March 2011). "The role of stress on physiologic responses and clinical
symptoms inirritablebowelsyndrome"Gastroenterology 140 (3):761–5.
38. Saito YA, Schoenfeld P, Locke GR (August 2002). "The epidemiology of irritable
bowel  syndrome  in  North  America:  a  systematic  review". Am.  J.
Gastroenterol. 97 (8): 1910–5.
39.Yang CM, Li YQ (2007). "[The therapeutic effects of eliminating allergic foods 
according to food-specific IgG antibodies in irritable bowel syndrome]". Zhonghua 
Nei Ke Za Zhi (in Chinese) 46 (8): 641–3. 
40. Stark D, van Hal S, Marriott D, Ellis J, Harkness J (2007). "Irritable bowel 
syndrome: a review on the role of intestinal protozoa and the importance of their 
detection and diagnosis". Int. J. Parasitol. 37 (1): 11–20
41.Paré P, Gray J, Lam S et al. (2006). "Health-related quality of life, work 
productivity, and health care resource utilization of subjects with irritable bowel 
syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of 
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy109
Chapter 8                                                                                                  Bibliography
Gastrointestinal Symptoms in Canada), a naturalistic study". Clinical 
therapeutics 28 (10): 1726–35; discussion 1710–1. 
42.Delvaux, M. and Wingate, D., Trimebutine: mechanism of action, effects on 
gastrointestinal function and clinical results. J. Int. Med. Res., 25, 225–246 (1997).
43.Farrugia, G., Ca2+ handling in human interstitial cells of Cajal. Gastroenterology, 
132, 2057–2059 (2007). 
44. Fioramonti, J. and Bueno, L., Centrally acting agents and visceral sensitivity. Gut,
51Suppl 1, i91–i95 (2002). 
45.Hwang, S. J., Blair, P. J., Britton, F. C., O’Driscoll, K. E., Hennig, G., Bayguinov, 
Y. R., Rock, J. R., Harfe, B. D., Sanders, K. M., and Ward, S. M., Expression of 
anoctamin1/TMEM16A by interstitial cells of Cajal is fundamental for slow wave 
activity in gastrointestinal muscles. J. Physiol., 587, 4887–4904 (2009). 
46.Kim, B. J., So, I., and Kim, K. W., The relationship of TRP channels to the 
pacemaker activity of interstitial cells of Cajal in the gastrointestinal tract. J. Smooth 
Muscle Res., 42, 1–7 (2006). 
47.Schmulson MW, Chang L (1999). "Diagnostic approach to the patient with 
irritable bowel syndrome". Am. J. Med. 107(5A): 20S–26S. 
48.Talley NJ (2006). "Irritable bowel syndrome" Intern Med J 36 (11): 724–8. 
49. Whitehead WE, Palsson O, Jones KR (2002). "Systematic review of the 
comorbidity of irritable bowel syndrome with other disorders: what are the causes and
implications?". Gastroenterology 122 (4): 1140–56.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy110
Chapter 8                                                                                                  Bibliography
50. "IBS and Depression Connection and Treatments". Webmd.com. Retrieved 2012-
10-21.
51.Holten KB, Wetherington A, Bankston L (2003)."Diagnosing the patient with 
abdominal pain and altered bowel habits: is it irritable bowel syndrome" Am Fam 
Physician 67 (10): 2157–62. 
52.  Essentials of medical pharmacology by K.D Tripati 6th edition pg no.461-3
53. statiatical approaches to establishing bioequivalence US food and drug 
administration centre for evaluation of drug and research . FDA. 2001
54. Draft guidelines  on reporting serious adverse events occurring in clinical trials  
by drugs controller  general, directorate general health sciences  central drug standard 
control organizations  new delhi dated 11-5-2011 
55. "Interstitial cystitis: Risk factors" .Mayo Clinic. January 20, 2009.
Dept.of Pharmacology                                                         JKKMMRF College of Pharmacy111
